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CHAPTER I 
 
INTRODUCTION 
 
DNA Topology 
 
DNA Structure and Implications of DNA Topology 
 Deoxyribonucleic acid (DNA) is a molecule primarily located in the nucleus of a 
cell that carries genetic instructions used in the cellular development, function, and 
reproduction of all known living organisms and many viruses.  
 DNA was first identified in the late 1860s by Swiss chemist Friedrich Miescher.
1
 
Decades later, the research efforts of other scientists, such as Phoebus Levene and Erwin 
Chargaff, revealed additional details about the DNA molecule, including its primary 
chemical components and the ways in which the nucleotides paired with one another.
1,2
 
In 1953, James Watson and Frances Crick, along with Rosalind Franklin and Maurice 
Wilkins, were the first scientists to formulate an accurate description of the double-
helical structure of DNA.
1-3
 In a follow-up publication to Watson and Crick’s famous 
paper describing the structure of DNA, they speculated on the implications of their 
discovery.
4
 The various problems of disentangling DNA strands or duplexes in a cell 
would be all rooted in the double-helical structure of DNA. Watson and Crick realized 
that the cell would require a mechanism to overcome the inevitable topological issues 
2 
that would arise due to the inherent and newly discovered properties of their DNA 
structure.
4
 Years later, James Wang discovered the first enzyme of many that had evolved 
to solve topological problems in the DNA. This enzyme was initially named the “ 
protein” but was later called DNA topoisomerase I.5 The details of how these enzymes 
work will follow after the inherent nature and challenges of DNA topology is described. 
 
DNA Topology  
It is important to first understand the nature of DNA structure that occurs in the 
cell. A typical DNA molecule consists of two complementary polynucleotide strands that 
are repeatedly intertwined every 10-10.5 bp into a double helix (Figure 1). In general, the 
length of chromosomal DNA in a cell far exceeds that of the cell it resides in. For 
example, the human genome contains approximately 2 meters of DNA, that must be 
compressed into the nucleus, which is only 5-10 µm in diameter.
6
 Thus, a number of 
mechanisms are employed to extensively organize the DNA into higher order 
conformations to efficiently compact all the information needed to carry out cellular 
processes (Figure 2).  
DNA is globally underwound by 6% in almost all living organisms.
7-13
 This is 
important because duplex DNA is the storage form of the genetic information. In order to 
replicate or express this information, the two strands of DNA must be separated to gain 
access to this genetic material. The fact that DNA is globally slightly underwound 
facilitates strand separation due to the decreased amount of energy needed to break the 
hydrogen bonds between the bases of DNA.
9,10,14
  
In all natural DNA, free rotation of the DNA ends is restricted, due to being 
typically circular in prokaryotes or tethered to the chromosomal scaffold in eukaryotes.  
3 
 
 
 
Figure 1. Structure of DNA. A typical DNA molecule (2 nm in width) and consists of 
two complementary polynucleotide strands repeatedly intertwined every 10-10.5 bp into 
a double helix is shown to the left. The sugar-phosphate backbones (grey) run anti-
parallel to each other, so that the 3’ and 5’ ends of the two strands are aligned. Within 
these two complementary strands two hydrogen bonds connect thymine (T) to adenine 
(A) while three hydrogen bonds connect guanine (G) to cytosine (C). Figure reproduced 
from Ref. 2. 
  
4 
 
 
 
Figure 2. Model of DNA compaction inside of a cell nucleus. The cell must handle 
amounts of DNA that are many times longer than the cells they are in. Thus, DNA 
packaging must be very efficient while still allowing for DNA replication and 
transcription to occur. An example of the levels of compactions the DNA must undergo 
to fit into the nucleus is depicted. Figure reproduced from Ref.15.  
5 
These types of attachments hinder the free rotation of the DNA strands and are 
considered a closed system. Consequently, DNA underwinding or overwinding induce 
torsional stress within the DNA molecule during processes that occur to replicate the 
DNA in the cell (Figure 3). When the stress is freely distributed along the DNA, some of 
it is converted to axial stress within the DNA duplex. Superhelical twists are formed from 
the DNA writhing about itself through the redistribution of stress. Hence, DNA under 
torsional and axial stress is referred to as supercoiled DNA.
7,10,13,16
 Accordingly, 
underwound and overwound DNA molecules are called negatively and positively 
supercoiled DNA, respectively.  
While the genetic information encoded in DNA is a one-dimensional array of 
bases, the three-dimensional structure of the genetic material controls how this 
information is replicated, expressed, and recombined in the cell.
17
 With the tight 
constraints of a closed system, the structure of DNA affects virtually every nucleic acid 
process that requires the double helix to be opened or moved within the cell.
13,17,18
 
Topological relationships of the DNA, such as overwinding, underwinding, knots, and 
tangles arise primarily from the fact that the two DNA strands are repeatedly intertwined. 
These topological relationships are defined as those that can be altered only by breaking 
one or both strands of the double helix.
13,17,18
 
 
Parameters of Supercoiled, Knotted, and Tangled DNA   
Supercoiled DNA has three fundamental parameters that are changed upon 
resolving the tension in the DNA duplexes: twist (Tw), writhe (Wr), and linking number 
(Lk). Tw represents the total number of double helical turns in a given segment of DNA. 
6 
 
 
Figure 3.  Topological challenges of DNA due to cellular processes. Nuclear processes 
induce changes in DNA topology. DNA replication is used as an example. Although 
chromosomal DNA is globally underwound in all cells, the movement of DNA tracking 
systems generates positive supercoils. (Top) The ends of chromosomal DNA are 
anchored to chromosome scaffold (represented by the red spheres) and are not free to 
rotate. Therefore, the linear movement of tracking systems (such as the replication 
machinery represented by the yellow bars) through the immobilized double helix 
compresses the turns into a shorter segment of the genetic material and induces acute 
overwinding (i.e. positive supercoiling) ahead of the fork (Middle). In addition, the 
compensatory underwinding (i.e. negative supercoiling) behind the replication machinery 
allows some of the torsional stress that accumulates in the pre-replicated DNA to be 
translated to the newly replicated daughter molecules in the form of precatenanes 
(Bottom). If these precatenanes are not resolved, they ultimately lead to the formation of 
intertwined (i.e. tangled) duplex daughter chromosomes. Figure reproduced from Ref. 19. 
  
7 
 Wr represents the number of times the double helix crosses itself if the molecule is 
projected in two dimensions. Lk is a numerical term that describes the sum of the twist 
and the writhe and represents the total linking within a DNA molecule. These properties 
of supercoiled DNA can be mathematically explained as Lk = Tw + Wr. The only way to 
change Lk is to introduce a break in one or both DNA strands, rotate the two DNA 
strands relative to each other, and reseal the break.
6,13,17 18 
Knots and tangles are controlled by two fundamental parameters: Wr and Lk.  
DNA crossovers that are present in knots and tangles are controlled by Wr and cannot be 
freely interconverted from Tw to Wr, as in the case of supercoiled DNA. The Lk of 
knotted or tangled DNA can only be changed by breaks introduced in both strands of 
DNA.
13,17,18
 
 
Challenges of DNA Topology  
DNA supercoiling is important in a number of biological processes, such as 
compacting DNA and regulating access to the genetic information.
20,21
 Separation of the 
two strands of the double helix must occur for transcription and replication to be carried 
out by RNA and DNA polymerases, respectively. As the two DNA strands are unwound 
by a polymerase-associated helicase, compensatory over- and under-winding occurs, due 
to the lack of free-end rotation. The replication or transcription machinery leads to 
positive supercoiling ahead of the fork and negative supercoiling behind (Figure 3).
13,18,22-
24
 Because the ends of DNA are fixed in space, critical cellular processes such as 
replication and transcription would stall before completion without a mechanism to 
relieve the torsional stress. Furthermore, torsional stress ahead of DNA tracking systems 
8 
is translated behind the fork and leads to the formation of precatenanes (Figure 3). 
Precatenanes link sister chromatids after replication and must be resolved in order for the 
chromosomes to be separated during mitosis.
9-11,13,18,23
 Accordingly, just as negative 
supercoiling can facilitate normal DNA processes, positive supercoiling can inhibit and 
ultimately block them if not alleviated.
9-11,13,14,18
 
Furthermore, during DNA replication, intermolecular links (catenanes) are formed 
between daughter DNA molecules. Unless these tangled DNA molecules can be 
decatenated, daughter chromosomes cannot be segregated during mitosis or meiosis. 
Likewise, intramolecular knots can be formed within the same DNA molecule and are 
generated during recombination. DNA knots block essential nucleic acid processes, 
because they make it impossible to separate the two strands of the double helix. 
Consequently, DNA knots and tangles can be lethal to cells if they are not 
resolved.
10,11,13,18,23
 
 
 
DNA Topoisomerases 
Enzymes Evolved to Resolve the DNA Topological Challenges 
Topoisomerases are nature’s solution to the topological complexities that occur in 
DNA.  These enzymes regulate the topological problems that naturally occur in DNA 
during cellular processes. Accordingly, DNA topoisomerases are essential for the 
survival of all organisms and alter DNA topology by generating transient breaks in the 
double helix.
19,23,25-28
 By creating transient breaks in the DNA, topoisomerases can then 
regulate the topology of the DNA through three main tasks: 1) maintaining appropriate 
chromosome topology, 2) removing positive supercoils, and 3) unlinking sister 
9 
chromatids during replication, strand separation, and cell division (Figure 4).
19,23,25-28
 
Thus, topoisomerases play essential roles in proliferating cells. 
All topoisomerases transiently cleave the DNA backbone by a nucleophilic attack 
using a catalytic tyrosine residue. The tyrosine residue then becomes covalently linked to 
the phosphate end of the DNA break. This covalent enzyme-DNA complex is known as 
the “cleavage complex” and is a hallmark catalytic event of topoisomerases. Religation of 
the DNA is highly favored and leaves the DNA sequence unchanged following the 
catalytic cycle of the enzyme.
19,23,25-29
 
Topoisomerases can be separated into two major classes, type I and type II. These 
classes are distinguished by the number of DNA strands that are cleaved and ligated 
during the catalytic cycle of their respective enzymes.
19,23,25-28,30-35
 The specific class of 
the enzyme is often denoted by numbers at the end of the name, with odd numbers 
signifying Type I enzymes and even numbers indicating Type II enzymes (Figures 4 and 
5). Type I topoisomerases transiently cleave a single strand of the DNA duplex, while 
type II topoisomerases cleave both strands. Furthermore, topoisomerases are further 
divided into subtypes (A, B, or C) comparing their sequence similarity, DNA interaction 
and/or global structure.
19,23,26-28,31-34,36
 
 
Type I Topoisomerases 
There are two main subclasses of type I topoisomerases: type IA and type IB 
(Figure 5). Type I topoisomerases act as monomers and alter the topology of supercoils 
by creating transient single-stranded breaks in the DNA, followed by passage of the 
opposite intact strand through the break (type IA) or by controlled rotation (swivel) of the 
10 
 
 
 
 
 
 
 
 
 
Figure 4. Topological challenges overcome by topoisomerases. A schematic is shown 
to indicate some of the cellular process in which topological challenges of DNA can 
occur and the role of topoisomerases to resolve the problem. (Top) During replication and 
transcription, the movement of the growing fork induces the formation of supercoils 
ahead of the fork and precatenanes behind the fork. In order for extensive DNA synthesis 
to proceed, the positive supercoils must be removed (relaxed). During recombination and 
repair, knots can form in the DNA and have to be unknotted (Middle). During mitosis, 
sister chromatids are tangled together. If the daughter chromosomes are not decatenated, 
cells will die of mitotic failure. To resolve these topological problems associated with 
DNA, cells possess enzymes called topoisomerases that function by creating transient 
breaks in the DNA to relax, unknot or decatenate the DNA. Figure produced by the 
Osheroff lab. 
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Figure 5. Generation of topoisomerase-DNA cleavage complex. (Top) Classification 
of human (A) and E. coli (B) DNA topoisomerases. The molecular masses (kDa), the 
prime end that the catalytic residue of the enzyme covalently links to (P-Y), and the 
change in linking number induced by the enzyme (∆Lk) are indicated. (Bottom) Double-
stranded DNA cleavage intermediates of the topoisomerase II are shown. The scissile 
bonds (red) are located four bases apart on opposite strands of the double helix. During 
cleavage, the active site tyrosine residue of each topoisomerase II protomer subunit 
becomes covalently linked to the newly generated 5’-terminal phosphate moiety on each 
strand. Ligation represents the reverse of this process and leaves the DNA product 
chemically unchanged from the initial substrate. Top figure adapted from Ref. 26 and  
bottom figure reproduced from Ref. 19. 
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 helix around the break (type IB). Type IA topoisomerases require divalent metal ions for 
DNA scission and attach covalently to the 5’-terminal phosphate of the DNA. In contrast, 
type IB enzymes do not require divalent metal ions and covalently link to the 3’-terminal 
phosphate.
18,19,23,26,27,29,31,32,36
 Type IA and IB topoisomerases differ in both structure and 
function.
26,27,36
 While Type IB enzymes can relax both positive and negative supercoils, 
Type IA can only relax negative supercoils.
19,23,26,27,31,32,34,36
   
Due to their single-stranded cleavage reaction mechanism, type I topoisomerases 
usually remove one supercoil at a time and change the Tw of the supercoil, altering the Lk 
by one. Therefore, Type I enzymes can modulate DNA under- and overwinding, but 
cannot remove knots or tangles from duplex DNA (Figure 4).
13,18
 These topological 
forms of DNA require type II topoisomerases, which I will focus on in the research 
presented. 
 
Type II Topoisomerases 
Type II eukaryotic enzymes act as dimers and relax (or in the case of gyrase 
induce) supercoils, untangle (decatenate), and unknot DNA due to their ability to cleave 
both strands of the double helix (Figures 4 and 5). These enzymes require ATP and 
divalent metal ions for overall catalytic activity.
37-39
 Briefly, type II topoisomerases 
modulate DNA topology by generating a transient double-stranded break in the DNA 
backbone, passing a separate double helix through the opening, and resealing the break 
(Figure 6). During the intermediate step of the catalytic cycle, type II enzymes covalently 
attach to the accessible 5’-terminal phosphates (4 base pairs apart on alternating strands) 
13 
created by the nucleophilic attack by the catalytic tyrosine residue of each monomer 
forming the “covalent complex” (Figures 5 and 6).19,23,25-27,31  
As a result of their double-stranded DNA passage mechanism, type II 
topoisomerases act solely on DNA writhes and remove two supercoils at a time. 
Therefore, they alter the Lk in steps of two. Because type II enzymes act on DNA writhes, 
they can remove knots and tangles from the genetic material.
13,18
 Importantly, at the end 
of replication, type II enzymes enable the segregation of newly replicated 
chromosomes.
19,28,40,41
 
All living organisms encode at least one type II topoisomerase.
26,31,42-45
 
Prokaryotic enzymes function as A2B2 heterotetramers and eukaryotic enzymes as 
homodimers. The prokaryotic and eukaryotic type II enzymes are homologous; in the 
eukaryotic type II homodimers (A2), the A and B subunits of the bacterial type II enzyme 
merge into a single subunit.
8,13,23,31,34,46-48
 
 Lower eukaryotes only encode one type II topoisomerase, while mammals 
express two isoforms of topoisomerase II, α and β. Human topoisomerase IIα and β are 
encoded by two separate genes (17q21–22 and 3p24, respectively) and differ in 
molecular mass (170 and 180 kDa, respectively). Both isoforms share extensive sequence 
identity (70%) and display similar enzymatic properties, but differ significantly in their 
expression, cellular regulation and functions.
8,26,44,49-53
 
 Expression of topoisomerase IIα is linked to cellular growth and is essential for 
the survival of proliferating cells.
18,19,25,27,35,48,54
 Overexpression of the enzyme is also 
monitored as a cancer cell marker.
27,28,36,55-57
 Protein concentrations of topoisomerase IIα 
are regulated over the cell cycle, increasing 2- to 3-fold during the G2/M phases.    
14 
 
 
 
 
Figure 6. Catalytic cycle of type II topoisomerases. In order for topoisomerase II to 
relax, untangle, or decatenate DNA: 1) the enzyme binds to a DNA crossover, positioning 
the G-segment (green)  of DNA in the DNA gate and the T-segment of DNA (yellow) 
within the N-gate. 2-3) In the presence of a divalent cation, the enzyme bends the G-
segment,  then cleaves and covalently attaches to DNA through the active site tyrosine 
residue. This covalent enzyme-DNA intermediate is known as the cleavage complex. 4) 
Through binding of ATP the N-gate closes and hydrolysis of 2 ATP induce 
conformational changes. These changes allow the enzyme to pass an intact T-segment 
through the cleaved G-segment. 5) The enzyme then religates the G-segment and 6) 
releases the T-segment 7) Hydrolysis of another ATP completes the catalytic cycle and 
allows the enzyme to releases the G-segment. Figure reproduced from Ref. 58. 
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Levels of the α isoform are virtually non-existent in quiescent and differentiated tissues, 
while rapidly proliferating cells contain ~500,000 molecules.
28,52
 The α isoform is 
associated with replication forks and remains tightly bound to chromosomes during 
mitosis. It also plays critical roles in DNA replication and recombination, and is required 
for proper chromosome organization and segregation.
23,28,30,47
  
 Expression of topoisomerase IIβ cannot compensate for the loss of topoisomerase 
IIα. Although the β isoform is not required at the cellular level, it is essential for neuronal 
development.
13,27,31,53,59,60
 High levels of the β isoform are found in most cell types, 
independent of proliferation status.
53,54,61
 Topoisomerase IIβ dissociates from 
chromosomes during mitosis but appears to play an important role in the transcription of 
hormonally and developmentally regulated genes.
53,62-64
 Despite the differences between 
the α and β isoforms of topoisomerase II, these enzymes are mechanistically similar and 
will be collectively referred to as topoisomerase II or type II enzyme, unless otherwise 
noted. 
 
Structural Domain Organization of Eukaryotic Topoisomerase II 
 On the basis of detailed structural and biochemical information, topoisomerase II 
enzymes are architecturally similar. Eukaryotic type II enzymes are homodimers with 
each protomer (~170 kDa) arranged symmetrically (Figure 7). Each protomer contains 
three main regions: N-terminal region (N-gate), cleavage/ligation region (DNA-gate or 
catalytic core), and C-terminal region (C-gate). The N-gate includes the Gyrase, Hsp90, 
Histidine Kinase, MutL (GHKL) domain and the transducer domain, which bind ATP 
and transduce hydrolysis signals to downstream regions of the enzyme, respectively. 
16 
 
 
 
 
 
   
 
Figure 7. Domain organization and structure of eukaryotic topoisomerase II. A 
diagram depicting the functional regions of topoisomerase II are colored and labeled 
above. A model of the ternary complex of yeast topoisomerase II is depicted below. 
One topoisomerase II protomer is shaded gray and the other is colored as depicted by the 
diagram. The green indicates the cleaved DNA contoured in 2Fo – Fc density. The C-
terminal region (CTR) is not present in the structure. Figure reproduced from Ref. 65. 
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The DNA gate contains the topoisomerase/primase (TOPRIM) domain that coordinates 
the divalent metal ions, and the winged-helix domain (WHD) that includes the active site 
tyrosine. The C-terminal domain (CTD) contains nuclear localization signals and post-
transcriptional modification sites. The CTD is largely disordered and less conserved 
among the type II enzymes.
66-68
 A schematic and structure of the domain organization can 
be seen in Figure 7. 
 
Catalytic Mechanism of Topoisomerase II 
 The multiple subunits of type II topoisomerases act through a complex 
mechanism to physically move one DNA duplex through another in order to help resolve 
DNA topological problems (Figures 6 and 7).
66,68-71
 In the DNA cleavage reaction, the 
dimer binds two segments of DNA at a crossover. The first segment bound by the 
enzyme is the double helix that will be cleaved by the enzyme and is referred to as the 
“Gate-” or “G-segment,” due to the location within the DNA-gate.72 The second segment 
is the double helix positioned in the N-gate that will be transported through the 
transiently cleaved G-segment and is referred to as the “Transport-”or “T-segment.”70 
Divalent metal ion(s) are then coordinated within the TOPRIM domain (located in the 
DNA-gate), and the type II topoisomerases sample the DNA for malleability.
38,65,72,73
 
Sequences within the G-segment that can be distorted to an ~150º angle are bent by the 
enzyme.
45,72
 Cleavage of the G-segment is then catalyzed by a nucleophilic attack on the 
DNA backbone, at sites located four bases apart on opposite strands of the double helix, 
using the active site tyrosine residue of each topoisomerase II protomer.
74-76
 Subsequently, 
the topoisomerase II protomers become covalently linked to the newly generated 5′-
18 
terminal phosphate moiety on each strand of the G-segment through a trans-esterification 
reaction (Figures 5 and 6). This assembly is called the “cleavage complex.” The 
topoisomerase II protomers bind two ATP within the ATPase domain (located in the N-
gate) and close the N-gate.
69,74
 Upon ATP hydrolysis, signals are transduced to 
downstream regions of the enzyme so that the T-segment is then transported through the 
DNA gate.
69,71,77
 The G-segment is then resealed, and the T-segment is 
released.
46,69,71,74,76,78
 After another ATP is hydrolyzed and the G-segment is released, 
enzyme is free to capture another crossover.
69,74,79
  
 
Cleavage-Ligation Balance 
The covalent enzyme-DNA linkage formed during DNA cleavage plays two 
important roles in the topoisomerase II reaction mechanism.
8,34,74,80,81
 First, it conserves 
the bond energy of the DNA backbone. Second, it maintains the integrity of the genetic 
material during the cleavage event, because it does not allow the cleaved DNA chain to 
dissociate from the enzyme.
34,80,82,83
 The cleavage complex is central to the catalytic 
cycle of the enzyme. The DNA cleavage/ligation equilibrium of the enzyme greatly 
favors ligation.
8,26,27,34,74,84-86
 Topoisomerase II-DNA cleavage complexes normally are 
short-lived and are readily reversible.
19,47,48,87
 Alterations by compounds or DNA lesions 
that increase the longevity of cleavage complexes have serious cellular 
consequences.
19,25-27,45
 
 Many type II topoisomerases are essential in proliferating cells. However, since 
these enzymes generate double-stranded DNA breaks as part of their reaction mechanism, 
they are intrinsically dangerous proteins. Thus, while essential to cell viability, the 
19 
enzymes also have the ability to fragment the genome (Figure 8). Because of this dual 
persona, levels of cleavage complexes are normally maintained in a critical 
balance.
19,25,27,36,68
 
When levels of cleavage complexes drop below threshold concentrations, 
daughter chromosomes remain entangled following replication. As a result, sister 
chromatids cannot properly segregate during mitosis and cells die due to catastrophic 
mitotic failure.
23,30,31,47,88,89
 When levels of cleavage complexes rise too high, cells also 
die, but for different reasons. In this instance, cell death is due to the conversion of 
transient DNA cleavage intermediates to permanent strand breaks.
90,91
 Permanent strand 
breaks are believed to be generated when replication forks, transcription complexes, or 
DNA tracking enzymes such as helicases attempt to traverse the covalently bound protein 
‘roadblock’ in the genetic material.19 ,56,91-95 The resulting damage and induction of 
recombination/repair pathways also can trigger mutations, chromosomal translocations, 
and other aberrations. When these permanent DNA breaks are present in sufficient 
numbers, they can overwhelm the cell and initiate cell death pathways.
19 ,56,90-95
  
 
Topoisomerase II Inhibitors vs. Poisons 
Compounds that alter topoisomerase II activity can be separated into two 
categories: topoisomerase II catalytic inhibitors and topoisomerase II poisons (Figure 8). 
Topoisomerase II catalytic inhibitors are chemicals that act by robbing the cell of the 
essential catalytic functions of the type II enzymes, and generally do not increase the 
concentration of cleavage complexes.
47,56,67,96,97
 Inhibitors have been shown to act at a 
variety of steps of the topoisomerase II catalytic cycle, including DNA cleavage. 
20 
 
 
 
 
 
Figure 8. Shifting the equilibrium of topoisomerase II DNA cleavage. A balanced 
level of topoisomerase II-DNA cleavage complexes is required for the enzyme to perform 
its critical cellular functions (blue). If the level of topoisomerase II-DNA cleavage 
complexes falls too low (left arrow, red), cells are not able to untangle daughter 
chromosomes and ultimately die of mitotic failure. If the level of cleavage complexes 
becomes too high (right arrow, red), the actions of DNA tracking systems can convert 
these transient complexes to permanent double-stranded breaks. The resulting DNA 
breaks, as well as the inhibition of essential DNA processes, initiate recombination/repair 
pathways and generate chromosome translocations and other DNA aberrations. If the 
strand breaks overwhelm the cell, they can trigger apoptosis. This is the basis of several 
widely prescribed anticancer drugs and natural products that target topoisomerase II. If 
the concentration of topoisomerase-mediated DNA strand breaks is too low to overwhelm 
the cell, mutations or chromosomal aberrations may be present in surviving populations. 
In some cases, exposure to topoisomerase II poisons has been associated with the 
formation of specific types of leukemia.  Figure adapted from Ref. 98. 
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Compounds that interact at these steps can be categorized by their ability to 1) prevent 
binding of the enzyme to the DNA, 2) compete for ATP binding, 3) inhibit ATP 
hydrolysis, and 4) block DNA cleavage.
47,67,96,97
   
 Alternatively, chemicals that increase levels of topoisomerase II-DNA cleavage 
complexes are said to “poison” the enzyme and convert it into a cellular toxin that 
initiates the mutagenic and lethal consequences.
91,94
 Thus, they are called “topoisomerase 
II poisons.” 19,47,89 Topoisomerase II poisons interfere with the ability of the enzyme to 
religate cleaved DNA molecules.
19,47,81,91,99
 Although some topoisomerase II poisons 
inhibit overall activity, the increased levels of cleavage complexes induced by these 
compounds in the cell is a “gain of function,” which is a dominant phenotype.48,87 All 
clinically relevant topoisomerase II-targeted drugs examined to date act as topoisomerase 
II poisons, and thus display anticancer properties as described in the topoisomerase II-
targeted drugs section.
19,47,81,91,99
 
 
Mechanisms of Topoisomerase II Poisons 
Topoisomerase II poisons act by two distinct mechanisms. Compounds that 
operate by the first mechanism are referred to as “interfacial poisons.” Interfacial poisons 
are chemicals that form non-covalent interactions with topoisomerase II at the protein-
DNA interface within the vicinity of the active site tyrosine. They also interact with DNA 
within the enzyme-DNA ternary complex and inhibit ligation by intercalating into the 
double helix at the cleaved scissile bond.
26,47,48,56,81,87
 A hallmark characteristic of 
interfacial poisons is their ability to present a physical barrier to ligation and act as 
“molecular doorstops.”56,81,89,100,101  
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 In contrast to interfacial topoisomerase II poisons, compounds that act by the 
second mechanism contain protein-reactive groups and are referred to as “covalent 
poisons.” 19,48,57,67,87 Most covalent poisons incorporate sulfhydryl-reactive groups.57,102-
105
 Covalent poisons act by adducting to the enzyme through an acylation reaction at 
amino acid residues outside of the active site.
57,104-107
 Additionally, their ability to poison 
topoisomerase II can be abolished by reducing thiol nucleophiles of the compound, 
rendering them unable to adduct to the reactive residues in the enzyme.
84,103,105,106,108
 
Finally, compounds that act as covalent poisons enhance DNA cleavage when added to 
the protein-DNA complex, but display the distinguishing feature of inhibiting 
topoisomerase II activity when incubated with the enzyme prior to the addition of 
DNA.
58,84,103,104,109-113
 Presumably, this may reflect the fact that closing the N-terminal 
protein gate prevents DNA binding.
104,111
 
Previous studies have shown that covalent poisons can accommodate a greater 
range of structural alterations than interfacial poisons.
58,84,102-106,111-115
 These findings 
suggest that covalent poisons act more as chemical modification reagents than “ligands” 
that require specific binding pockets on topoisomerase II. Furthermore, some covalent 
topoisomerase II poisons have been found to alter enzyme function, at least in part, by 
enhancing protomer crosslinking and N-terminal protein clamp closure.
102,104,107
 These 
studies suggest a mechanistic basis for stabilizing pre-existing cleavage complexes, while 
preventing DNA binding of unoccupied enzymes.
19,57,67
 However, additional possibilities 
cannot be excluded, and the detailed mechanisms by which covalent topoisomerase II 
poisons increase levels of DNA cleavage complexes have yet to be determined.  
23 
Notably, the actions of interfacial topoisomerase II poisons are not affected by 
reducing agents, such as dithiothreitol (DTT), and these compounds induce similar levels 
of enzyme-mediated DNA cleavage whether they are added to the enzyme-DNA complex 
or are incubated with the enzyme prior to the addition of DNA.
48,103,116,117
 
 
Topoisomerase II-Targeted Drugs 
 
Targeting Topoisomerase II 
The immense interest in topoisomerase II in recent years derives not only from 
the recognition of their crucial role in managing DNA topology, but also from major 
advances in identifying targets of cytotoxic drugs. Notably, topoisomerase IIα is 
overexpressed in rapidly proliferating cells such as tumor and bacterial cells and is an 
ideal target for anticancer and antibacterial drugs. A wide variety of topoisomerase-
targeted drugs, some of which are currently in widespread clinical use, have been 
discovered to generate enhancement of cytotoxic lesions by trapping the enzymes in 
covalent enzyme-DNA complexes, thus leading to cytotoxicity in rapidly proliferating 
cells. These topoisomerase II-targeted drugs function as topoisomerase II poisons and can 
be utilized as anticancer or antimicrobials chemotherapeutics.
19,26,36,47,56,76
 
 
Clinically Relevant Topoisomerase II Poisons 
Topoisomerase II poisons represent some of the most successful and widely 
prescribed anticancer drugs worldwide.
19,28,36,48,56,57
 Currently, six topoisomerase II-
targeted agents are approved for use in the United States.
19,28,36,48,56,57,67,118
 These drugs 
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encompass a group of naturally derived and synthetic compounds and are used to treat a 
variety of human malignancies (Figure 9). Notably, etoposide, doxorubicin, and their 
derivatives are highly active anticancer agents and are frontline therapies for a number of 
systemic cancers and solid tumors, including leukemias, lymphomas, sarcomas, breast 
cancers, lung cancers, neuroblastoma, and germ-cell malignancies.
19,28,36,56,57
 
Furthermore, mitoxantrone is used to treat breast cancer, acute myeloid leukemia (AML), 
and non-Hodgkin lymphoma, and amsacrine is used to treat relapsed acute myeloid 
leukemia.
28
 Ultimately, half of all anticancer regimens include topoisomerase II-targeted 
drugs.
19,28,36,56,57
 
Etoposide is by far the best-characterized topoisomerase II 
poison.
94,99,101,113,116,119-123
 Research involving this drug has provided a knowledge-base 
that has paved the way for later work on other anticancer agents. Etoposide was one of 
the first chemotherapeutic drugs demonstrated to kill cells by targeting topoisomerase II 
and inhibiting the DNA ligation activity of the type II enzyme.
90,94,99,101,113,115,116,119-126
 
Etoposide is an interfacial topoisomerase II poison that enters the binary enzyme-DNA 
complex primarily through interactions with the protein.
116
 Recent structural data with the 
drug has helped to reveal structure-function relationships with the topoisomerase II-DNA 
complex.
67,68,101,127-129
 
 
Non-Intercalating vs. Intercalating Topoisomerase II Poisons 
Topoisomerase II poisons can be further subdivided into non-intercalating and 
intercalating poisons, with clinically relevant drugs in both categories. Non-intercalating 
topoisomerase II poisons include the epipodophyllotoxins, etoposide and teniposide, and 
25 
 
 
 
 
 
Figure 9. Clinically relevant topoisomerase II anticancer drugs. The demethyl-
epipodophyllotoxins etoposide, etoposide phosphate, and teniposide, the anthracyclines 
doxorubicin, daunorubicin, and idarubicin, and the anthracenedione mitoxantrone are 
approved for clinical use in the United States.   
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 fluoroquinolones and have the ability to trap topoisomerase II-DNA covalent 
complexes. These non-intercalative compounds do not strongly interact with the DNA 
substrate, but mainly act through association with the protein.
101,130-132
 Recent structural 
details reveal the detailed interactions between topoisomerase II, DNA, and the non-
intercalative drug, etoposide. In the ternary complex, two etoposide molecules bind 
between the base pairs immediately flanking the two cleaved scissile bonds. This 
interaction is mediated by direct contacts with surrounding residues of topoisomerase II. 
Consequently, the protein-DNA-drug association stabilizes the cleavage complex by 
physically blocking the topoisomerase II-mediated resealing of DNA.
101
 
The intercalators are chemically diverse and include compounds such as 
doxorubicin, daunorubicin, mitoxantrone, mAMSA, and a variety of other compounds 
that are not currently in clinical use (ie. amonafide and ellipticine).
56
 Topoisomerase 
poisons that act as intercalators, usually contain a planar tri- or tetracycline ring base. The 
planar structure is usually positioned between the +1/-1 base positions within the cleaved 
G-segment, inhibiting the ability of the G-segment to religate. Anthracyclines 
(doxorubicin, daunorubicin, and their derivatives) can affect a broad range of DNA 
processes by intercalation and undergo redox reactions that generate reactive oxygen 
species (ROS), which have been implicated in their dose-limiting cardiotoxicity.
26,56
 
 
Natural Products as Anticancer Drugs 
 A “natural product” is generally regarded as being a secondary metabolite from a 
natural source. Natural products are organic substances (< 3 kDa) that are structurally 
diverse throughout nature. These compounds are derived from plants, microbes, and 
27 
marine sources, and can be either naturally active within the source to support the species 
survival or be a byproduct of the specie’s metabolism.133,134 
  Humans have relied on natural products as a medicinal resource for thousands of 
years. Notably, plant-based drugs have formed the basis of traditional medicine that has 
been used for centuries in Egypt, China, and India.
134-136
 In the majority of developing 
countries, particularly those in Asia, Africa, Latin America, and the Middle East, between 
70-95% of citizens still use traditional and herbal medicines for primary health care and 
management. In some industrialized nations, use of traditional medicine is equally 
significant due to cultural and historical influences, as well as preference for 
complementary therapy. For instance, Canada, France, Germany, and Italy report that 
between 70-90% of their populations have used traditional medicines under the titles 
“complementary,” “alternative,” or “nonconventional.” The ongoing use of traditional 
therapy is not surprising, given that until the middle of the 20th century and the 
introduction of “modern medication,” traditional remedies were the only medicines 
available.
137,138
 
 Natural products have been the single most productive source of leads for the 
development of drugs.
139,140
 Since the 1930s, over 180 anticancer drugs have been 
developed, and more than half of these drugs came from or were based on natural 
products (Figure 10).
135,140,141
  
 Anticancer drugs have been established by utilizing natural products in a number 
of ways: naturally occurring (unmodified), naturally derived (modified), or synthetically 
mimicked forms.
135,136,140-142
 Hence, a number of microorganism-derived compounds 
have been developed as anticancer drugs, such as anthracyclines (ie. doxorubicin and  
28 
 
 
 
 
Figure 10. Naturally derived compounds in anticancer drug development. From  
1930- 2010, over 180 anticancer drugs were developed and nearly half of those drugs 
were developed from natural products. Depicted in this pie graph are the sources of the 
drugs. These drugs range from direct natural products to synthetic mimics and derivatives 
of natural products. Note, less than 25% of the drugs developed had nothing to do with 
natural products. Figure reproduced from Ref. 140. 
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daunorubicin), bleomycin, dactinomycin (actinomycin), and mitomycin C. Some of the 
most beneficial antitumor agents are derived from plants and are categorized based on 
their relationship to four main compounds: bisindole (vinca) alkaloids, camptothecins, 
epipodophyllotoxins, and taxanes. In addition, there are several examples of promising 
natural product-derived antineoplastic agents that are currently in advanced clinical 
development or have been recently approved from microbial, plant, and marine 
origin.
136,141
 
  
Natural Products Targeting Topoisomerase II Activity 
 
Naturally Derived Topoisomerase II Poisons Used in the Clinic 
A number of topoisomerase II-targeted drugs are derived from natural 
sources.
57,96
 Of the number of clinically relevant antitumor agents derived from plants 
and microbes (camptothecin, anthracycline and epipodophyllotoxin-based compounds), 
many of them target topoisomerase activity. These drugs typically function as interfacial 
poisons, as they inhibit DNA religation and enhance levels of stable topoisomerase-DNA 
cleavage complexes, ultimately leading to apoptosis.
19,26,36,56,118,120
 
One of the first topoisomerase II-targeted agents to be developed was etoposide, 
which is derived from podophyllotoxin. This natural product is found in Podophyllum 
peltatum, also known as the mayapple or American mandrake plant. Podophyllotoxin has 
been used as a folk remedy for over a thousand years.
121,125
 Although clinical use of 
podophyllotoxin as an antineoplastic agent was prohibited due to high toxicity, two 
synthetic analogs, etoposide and teniposide, were developed. These analogs displayed 
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increased antineoplastic activity and decreased toxicity compared to the parent 
compound. Importantly, the target changed from tubulin to topoisomerase II when the 
parent compound was derivatized to these two analogs. 
121,125
 
In addition, doxorubicin and daunorubicin are produced by the bacterium 
Streptomyces peucetius.
143
 Doxorubicin, daunorubicin, and related compounds 
(idarubicin and epirubicin) are anthracyclines that act as antitumor antibiotics. These 
anthracyclines are among the most used drugs used in chemotherapy and exert antitumor 
activity mainly by inhibiting the religation of topoisomerase II-DNA cleavage.
26,47,56,67,144
 
 
Dietary Topoisomerase II Poisons  
Several naturally occurring dietary compounds act as topoisomerase II 
poisons.
57,84
 These include bioflavonoids (flavones, isoflavones, and flavonols), 
isothiocyanates, quinones (curcumin oxidation products and thymoquinone), and 
catechols (epigallocatechin gallate [EGCG]).
58,105,112,145-147
 Many of these compounds act 
as covalent topoisomerase poisons, but some can exert their effects through an interfacial 
poison mechanism.
57
 
Bioflavonoids are a diverse group of polyphenolic compounds that are 
constituents of many fruits, vegetables, legumes, and plant leaves. Studies suggest that 
these compounds help protect against cancer, cardiovascular disease, osteoporosis, age-
related diseases, and inflammation.
148-153
 Although bioflavonoids exert a range of effects 
on human cells, a number of them are potent topoisomerase II poisons in vitro and in 
cellulo.
145,154-157
 Notably, most bioflavonoids do not require redox cycling for activity and 
function primarily by inhibiting enzyme-mediated DNA ligation. Many of the 
31 
chemopreventive, cytotoxic, and genotoxic properties of flavones, isoflavones, and 
flavonols are consistent with their activities as topoisomerase II poisons.
57,145,152,154,155
 
Flavone, isoflavone, and flavonol classes of bioflavonoids are interfacial 
topoisomerase II poisons (Figure 11).
146,154
 In general, structure-function assays showed 
that the presence of a hydroxyl moiety at the 5- or 4′-position of the bioflavonoids, as in 
the case of genistein, greatly contributes to the enhancement of enzyme-mediated DNA 
cleavage.
145,155
 Among the bioflavonoids, genistein has the highest activity against the 
human type II enzymes as an interfacial poison, which was correlated to its cytotoxic 
effects in cellulo.
145,154,158,159
 Genistein is one of the most abundant isoflavones in soy. 
While the main source of genistein is soybeans, other legumes, such as chickpeas, also 
contain small amounts.
57,141,154-156
  
Catechins represent another important class of bioflavonoids (Figure 11).
150,151
 
Green tea, which is one of the most commonly consumed beverages in the world, is a rich 
source of catechins and has been suggested to reduce the incidence of breast, prostate, 
colorectal, and lung cancer in humans. The most abundant catechins in green tea are 
EGCG and related compounds.
141,146,153,160-164
 Although EGCG is a potent topoisomerase 
II poison, it appears to be a covalent, rather than an interfacial, topoisomerase II 
poison.
146,147
 The mechanistic differences between bioflavonoid classes appear to be 
related to structural elements in the B and C rings in the compound. While the C-4’ 
hydroxyl of the B-ring is critical for bioflavonoids to act as interfacial topoisomerase II 
poisons, the inclusion of two additional B-ring hydroxyl groups increases redox activity 
and is required for compounds to act as covalent topoisomerase II poisons. Because 
EGCG contains a catechin C-ring, it is unable to act as interfacial topoisomerase II  
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Figure 11. Structures of selected bioflavonoids. Top) Flavones, flavonols, and 
isoflavones are shown, and the ability of each to enhance topoisomerase II-mediated 
DNA cleavage is indicated as >8-fold (+++), 6- to 8-fold (++), 3- to 6-fold (+), 2- to 3-
fold (+/–), or <2-fold (–) over baseline. Bottom) The structure of the green tea catechin, 
EGCG, is shown. EGCG has the ability to enhance topoisomerase II-mediated DNA 
cleavage as well, but through a different mechanism. Adapted from Ref. 145.   
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poison and functions exclusively as covalent poison.
146,147
 Notably, if three hydroxyl 
groups are included on the B-ring of a flavonol, the compound can act as a dual function 
topoisomerase II poison that displays both interfacial and redox-dependent characteristics 
(Figure 11).
57,146,147
 
Another source of dietary topoisomerase II poisons can come from glucosinolates, 
which are sulfur-containing glucosides found in cruciferous vegetables, such as broccoli, 
cabbage, cauliflower, and kale (Figure 12).
165,166
 Many natural isothiocyanates are 
produced from these glucosinolates and inhibit cell proliferation, display 
chemopreventive properties, and inhibit tumor growth in xenograft models.
167-169
 
Isothiocyanates are topoisomerase II poisons in vitro.
105
  Silencing topoisomerase IIα in 
cellulo decreases DNA damage induced by isothiocyanates. Similar to reactive quinone-
based topoisomerase II poisons, isothiocyanates act as covalent poisons and modify 
several cysteine residues in human topoisomerase IIα. Consistent with the covalent 
poison mechanism, the ability of isothiocyanates to induce topoisomerase II-mediated 
DNA cleavage is abolished when the compounds are reduced by prior incubation with 
excess glutathione.
105
  
 Additionally, some herbs and spices have been found to act as topoisomerase II 
poisons (Figure 12). For example, curcumin, which undergoes spontaneous autoxidation, 
in aqueous solution at a physiological pH, goes through an oxidation intermediate within 
its oxidation pathway that alters topoisomerase activity. The oxidation intermediate acts 
as a covalent topoisomerase II poison, while the parent compound and the stable final 
product have no effect on enzyme activity.
58,170,171
 Even in the complex formulation of 
turmeric, oxidized curcumin intermediates appear to function as topoisomerase II 
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Figure 12. Structures of dietary and related compounds. Left) Structures are shown of 
sulfur-containing isothiocyanates that are natural products from cruciferous vegetables 
(broccoli, cabbage, cauliflower, and kale). These isothiocyanates act as covalent poisons 
and modify several cysteine residues in human topoisomerase IIα. Top) The polyphenol 
curcumin is shown. Curcumin is the principal flavor and color component of the spice 
turmeric. An oxidation intermediate of curcumin acts as a covalent poison. Bottom) 
Thymoquinone is major bioactive compound of black seed and was found to act as a 
covalent topoisomerase II poison even in its herbal formulation. The similar quinones 
alongside the thymoquinone structure also enhance topoisomerase II-mediated DNA 
cleavage.  Dietary compounds are bolded. 
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 poisons.
58
 The polyphenol curcumin is the principal flavor and color component of the 
spice turmeric. Beyond its culinary uses, curcumin is believed to positively impact human 
health and displays antioxidant, anti-inflammatory, antibacterial, and chemopreventive 
properties.
172-175
 Over the years, more than 100 clinical research trials have been initiated 
to investigate curcumin and its metabolites as a plausible regimented therapy (clinical 
trials.gov). 
 Adding to the growing list of dietary and medicinal natural products with activity 
against human type II topoisomerases, thymoquinone, the major bioactive compound of 
black seed, was found to act as a covalent topoisomerase II poison even in its herbal 
formulation.
112
 Black seed is a Mediterranean herb with a rich history of medicinal use. 
Historically, the medicinal herb has been used to treat a variety of illnesses associated 
with inflammation and displays anticancer activity in cellular and animal models.
176-180
 
Noticeably, thymoquinone shares structural features with quinone-like covalent 
topoisomerase II poisons (Figure 12).
57,103,110,112
 
 All in all, dietary agents including fruits, vegetables, and spices have drawn a 
great deal of attention from both the scientific community and the general public due in 
part to their demonstrated ability to suppress cancers. Over the past 20 years, studies have 
suggested that diets rich in fruits, vegetables, and spices leads to a lower incidence of 
cancers (stomach, esophagus, lung, oral cavity and pharynx, endometrium, pancreas, and 
colon).
93,141,148-152,165,166
 Although traditional herbal medicine usage has been stifled since 
the introduction of modern medicine, researchers and the public are still interested in the 
wealth of information to be gained from naturally occurring sources for the purposes of 
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chemopreventative, alternative, and anticancer therapy, as well as for drug discovery and 
development.  
 
Topoisomerase II-Associated Leukemias and Side Effects  
Although topoisomerase II is an important target for chemotherapeutic and 
chemopreventive agents, there are unfortunate secondary effects that can accompany 
treatment with topoisomerase II poisons. Evidence suggests that use of some of the 
frontline therapies used to target topoisomerase II can cause chromosomal translocations 
that can lead to specific leukemias. About 2-3% of patients treated with etoposide and 
other topoisomerase II-targeted regimens are eventually diagnosed with treatment-related 
leukemias such as acute myeloid leukemia (AML).
19,28,48,95,125,181-184
 Most of these 
leukemias are characterized by translocations with breakpoints in the mixed lineage 
leukemia (MLL) gene at chromosomal band 11q23. Several breakpoints in the MLL gene 
have been identified and are located in close proximity to topoisomerase II-DNA 
cleavage sites that are induced by etoposide.
95,183,185,186
 
 In addition to treatment-related leukemias, ~80% of infants with AML or acute 
lymphoblastic leukemia (ALL) display translocations that involve the MLL gene. The 
chromosomal translocations associated with these cancers have been observed in utero, 
indicating that infant leukemias are initiated during gestation.
28,187,188
 Epidemiological 
studies indicate that the risk of developing these infant leukemias increases more than 3-
fold when pregnant women consume foods/drinks that are rich in bioflavonoids (i.e. soy 
and green tea) and other naturally occurring topoisomerase II poisons.
28,187-190
 Similarly, 
treatment of cultured human cells with dietary bioflavonoids induces cleavage within the 
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MLL gene. Compounds that display the highest in vitro topoisomerase II-DNA cleavage 
activity tend to show the greatest propensity to generate breaks in the MLL gene in 
cultured cells.
189
 Consequently, the same topoisomerase II activity that is essential for 
normal cell growth and that is targeted to treat a number of human malignancies can be 
disadvantageous when targeted by phytochemicals or topoisomerase poisons used in 
treatment, possibly leading to leukemia through chromosomal translocations.  
Moreover, mounting evidence suggests that topoisomerase IIβ is the isoform 
primarily responsible for initiating at least some topoisomerase II–associated secondary 
malignancies.
12,28,56,191,192
 A recent study demonstrated that a cardiomyocyte specific 
deletion of topoisomerase IIβ protected mouse hearts from doxorubicin-induced DNA 
and mitochondrial damage. Since expression of topoisomerase IIα, but not topoisomerase 
IIβ, is proliferation dependent, differentiated tissues almost exclusively express the β 
isoform.
28,53
 While the precise mechanism by which doxorubicin and other drugs induce 
cardiac damage remains controversial, research has begun to elucidate the actions of the 
drug against topoisomerase IIβ as a likely cause of cardiotoxicity.12,193 
Nonetheless, targeting topoisomerase II has been extremely successful in a variety 
of settings (i.e. anticancer and chemopreventive). Thus, there is still a need to identify 
new agents that target topoisomerase II, as well as to further understand the detailed 
mechanism (structure-functions relationships, isoform specificity, and side effects) of 
currently used topoisomerase II-targeting agents.  
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Scope of Dissertation 
 
Beyond the critical cellular functions of topoisomerase II, the enzyme is the target 
for a number of widely prescribed anticancer drugs that are used in the treatment of 
breast, lung, and prostate cancer, sarcomas, and hematological malignancies. With a 
broad spectrum of anticancer drugs having emerged directly from natural sources or 
derived from natural products, it is no surprise that they include a number of compounds 
that alter topoisomerase II activity.  
The dissertation research presented here is focused on characterizing the 
mechanism by which natural products enhance human topoisomerase IIα-mediated DNA 
cleavage. The goals of the research presented are to identify naturally derived compounds 
that alter human topoisomerase II activity and to characterize their mechanism of action. 
Compounds that were originally extracted from natural sources or were synthesized as a 
derivative of a natural parent compound were examined for activity against 
topoisomerase II. These include a library of water-soluble extracts from Mediterranean 
plants, olive leaf metabolites, ellipticine-based compounds, and quinone-type compounds 
from the fungus Septofusidium berolinense. 
Chapter I reviews the fundamentals needed to understand topoisomerase function 
and purpose, as well as the importance of identifying and understanding new 
topoisomerase II-targeting drugs and chemopreventatives from natural sources. Chapter 
II describes the materials and methods used in the research presented in Chapters III-V 
and the appendix. 
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Chapter III identifies and characterizes new phytochemicals that enhance 
topoisomerase II-mediated DNA cleavage from a double-blind screen of a library of 341 
Mediterranean plant extracts. Results indicated that an extract from Phillyrea latifolia L., 
a member of the olive tree family, displayed high activity against the human enzyme. 
Metabolites found in the complex formulation of olive leaves, fruit, and oil enhanced 
topoisomeraseII-mediated DNA cleavage. Specifically, hydroxytyrosol, oleuropein, and 
verbascoside displayed hallmark characteristics of covalent topoisomerase II poisons. 
The potency of these olive metabolites increased 10– to 100–fold in the presence of an 
oxidant. This research was published in Biochemistry.
194
  
Chapter IV describes the investigation of two potential topoisomerase II-targeting 
drugs using two ellipticine-based compounds, ET-1 and ET-2. Through a series of 
biochemical assays, the new ellipticine derivatives were determined to act as catalytic 
inhibitors of human topoisomerase IIα and are both more potent than the parent 
compound, ellipticine. The potency of ET-1 and ET-2 as catalytic inhibitors of 
topoisomerase IIα appeared to be related to their ability to intercalate into the double 
helix. This research was published in Bioorganic & Medicinal Chemistry Letters.
195
 
Chapter V describes the quest to uncover the basis for which two recently 
identified fungal compounds, GE-1 and GE-2, display cytotoxic activity towards a 
variety of human cancer cell lines by assessment towards topoisomerase II activity. The 
quinone compound, GE-2, was characterized as a covalent topoisomerase II poison and 
enhanced DNA cleavage ~4–fold. In contrast to GE-2, the hydroquinone, GE-1, did not 
enhance DNA cleavage mediated by topoisomerase IIα. However, the activity and 
potency of GE-1 was dramatically enhanced under oxidizing conditions. Results from 
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these studies suggested that topoisomerase IIα may play a role in mediating the cytotoxic 
effects of these fungal metabolites. This research was published in Chemical Research in 
Toxicology.
196
 
Concluding remarks for the research presented in this dissertation are provided in 
Chapter VI.  
In the appendix, research that describes the pursuit to better understand the 
possible adduction sites of covalent poisons on human topoisomerase IIα is presented. 
This research was focused on the effects of cysteine to alanine mutations at residues 104, 
427, and 427/455 on enzyme activity. Follow-up studies compared His-tagged wild-type 
to the His-tagged C104A enzyme activity with both the interfacial poison etoposide and 
the covalent poison hydroxytyrosol. These studies were carried out using site-directed 
mutagenesis of human topoisomerase IIα, enzyme purification, and activity assays.  The 
appendix also contains the materials and methods prepared by our collaborators. 
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Materials 
 
Enzymes 
 Recombinant wild-type human topoisomerase IIα, topoisomerase IIβ, and 
Top2α∆1175 [a deletion mutant (residues 1-1175) of human topoisomerase IIα] were 
expressed from the galactose-inducible YEpWob6 plasmid (12.07kb) in Saccharomyces 
cerevisiae JEL-1Δtop1 and purified as described previously.197-200 A modified YEpWob6 
vector containing the wild-type human topoisomerase IIα gene and a C-terminal c-myc 
and hexahistidine tag (6XHis) 
201
 was obtained from Dr. Joseph Deweese (Lipscomb 
University). Recombinant 6XHis- human topoisomerase IIα and mutants were generated, 
expressed, and purified as indicated in the procedures section below. The catalytic core of 
human topoisomerase IIα (residues 431-1193) was a gift from J. Deweese and was 
expressed and purified as described previously.
66,201,202
 Enzymes were stored in liquid 
nitrogen (long-term storage) or at -80 °C as a 1.5 mg/mL stock in 50 mM Tris-HCl, pH 
7.9, 0.1 mM EDTA, 750 mM KCl, 5% glycerol. The residual concentration of 
dithiothreitol was <2 µM in final reaction mixtures. Human topoisomerase I was obtained 
from Invitrogen. 
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DNA Substrates   
Negatively supercoiled pBR322 DNA was prepared from Escherichia coli using a 
Plasmid Mega Kit (Qiagen) as described by the manufacturer. Kinetoplast DNA (kDNA) 
was isolated from Crithidia fasciculata as previously described.100 Relaxed pBR322 
plasmid DNA was generated by treatment with topoisomerase I for 30 min as previously 
described,101 followed by a PCI extraction, ethanol precipitation, and resuspension in 5 
mM Tris-HCl (pH 8.5) and 500 μM EDTA. Linear radiolabeled pBR322 was prepared as 
follows. The pBR322 DNA plasmid was linearized by treatment with HindIII, and 
terminal 5’-phosphates were removed and replaced with [32P]phosphate by treatment with 
calf intestinal alkaline phosphatase followed by T4 polynucleotide kinase and [-
32
P]ATP. The labeled DNA was linearized using EcoRI, and the 4330 bp singly-end-[
32
P] 
labeled fragment was purified from the short EcoRI-HindIII fragment by passage through 
a CHROMA SPIN+TE-100 column (Clontech). 
 
Reagents 
 Analytical grade etoposide, DL-dithiothreitol (DTT), adenosine 5′-triphosphate 
(ATP) disodium salt hydrate, was purchased from Sigma-Aldrich. Etoposide was 
prepared as a 20 mM stock in 100 % DMSO and stored at room temperature. DTT and 
ATP were prepared as 500 mM and 20 mM stocks, respectively, and stored at  -20 °C. 
Potassium ferricyanide [K3Fe(CN)6] was obtained from Acros and was stored at 4 C as a 
50 mM stock solution in deionized purified water. [γ-32P]ATP (5000 µCi) was purchased 
from Perkin Elmer and stored at -20 °C. 
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Olive Leaf Metabolites 
  Analytical grade tyrosol (4-hydroxyphenylethanol), DMPE (3,4-
dimethoxyphenylethanol), HMPE (4-hydroxy-3-methoxyphenylethanol), and oleuropein 
were purchased from Sigma-Aldrich. Analytical grade hydroxytyrosol (3,4-
dihydroxyphenylethanol), verbascoside, and caffeic acid (3,4-dihydroxyphenylpropionic 
acid) were obtained from LKT Laboratories. Tyrosol, hydroxytyrosol, oleuropein, 
verbascoside, and 4-hydroxy-3-methoxyphenylethanol were prepared as 20 mM stocks in 
deionized purified water and stored at -20 °C. Caffeic acid, 3,4-dimethoxyphenylethanol, 
and 4-hydroxy-3-methoxyphenylethanol were prepared as 20 mM stocks in 100 % 
DMSO and stored at room temperature.  
 
Ellipticine and Derivatives 
Analytical grade ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole) was 
purchased from Sigma-Aldrich. The ellipticine derivatives N-methyl-5-demethyl 
ellipticine (ET-1) and 2-methyl-N-methyl-5-demethyl ellipticinium iodide (ET-2) were 
synthetically generated as described in the appendix and provided to us by Zeki Topcu. 
Compounds were prepared as 20 mM stock solutions in 100% DMSO and stored at 4 ºC.  
 
Quinone-like Compounds 
Two quinone-type compounds, 3,6-dihydroxy-2-propylbenzaldehyde (GE-1) and 
2-hydroxymethyl-3-propylcyclohexa-2,5-diene-1,4-dione (GE-2), were isolated from the 
ascomycete fungus S. berolinense as part of a search for new bioactive secondary 
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metabolites.
203
 GE-1 and GE-2 were provided by Zeki Topcu. Compounds were prepared 
as 50 mM stock solutions in 100% DMSO and stored at 4 ºC.  
 
Plant Extracts  
A library of methanol/water extracts from 341 native Mediterranean plants, 
mainly from arid lands, the Tel Aviv University Botanical Garden and traditional 
Bedouin medicinal plants.
204-206
 Based on results with the original library, a second 
library of 36 extracts from the leaf, bark, flowers, or fruit of 11 individual olive tree 
species was established.  
 Plant extracts were prepared as described by Kaiser et al.
207
 The 341 plants extracts 
were resuspended in deionized purified water at a final concentration of 2 mg/mL and 
screened in a blind fashion. Samples from the olive tree extract library were prepared as 
described above, resuspended to a final concentration of 10 or 20 mg/mL in deionized 
purified water, and stored at -20 °C.  
 
Commercial Extracts 
  Commercial olive leaf extract (Olive Leaf Plus
TM
, ~30% oleuropein) was 
purchased from Life-Flo and prepared as a 20 mg/mL stock in deionized purified water. 
The manufacturer did not identify the species of olive leaves used in this preparation. 
Extra virgin olive oils, pressed from the indicated subspecies of O. europea, including 
Olive Oil Store Ultra Arbosana (arbosana olives), Olive Oil Store Ultra Koroneiki 
(koroneiki olives), and Lucini Select (a mixture of frantoio, moraiolo, leccino, maurino, 
and pendolino olives), were stored at room temperature. Soluble extra virgin olive oil 
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extracts were prepared by vigorously vortexing a 1:1 mixture of oil and deionized 
purified water for 5 min, using 30 s pulses. The oil and water phases were separated by 
centrifugation at 8,000 x g for 10 min, at room temperature, and the aqueous phase was 
used for subsequent experiments.  
 
Procedures  
 
Plasmid DNA Cleavage 
DNA cleavage reactions were performed as described by Fortune and Osheroff.
208
 
Reaction mixtures contained 110 nM human topoisomerase IIα or 430 nM topoisomerase 
IIα catalytic core and 10 nM negatively supercoiled pBR322 DNA in a total of 20 µL of 
cleavage buffer [10 mM Tris-HCl (pH 7.9), 5 mM MgCl2, 100 mM KCl, 0.1 mM EDTA, 
and 2.5% (v/v) glycerol]. DNA cleavage reaction mixtures were incubated at 37 °C for 6 
min, and enzyme-DNA cleavage complexes were trapped by the addition of 2 μL of 5% 
SDS followed by 2 μL of 250 mM EDTA (pH 8.0). Proteinase K (2 μL of a 0.8 mg/mL 
solution) was added, and samples were incubated at 45 °C for 30 min to digest the type II 
enzyme. Reaction samples were mixed with 2 µL of agarose loading dye [60% sucrose in 
10 mM Tris-HCl pH 7.9, 0.5% bromophenol blue, and 0.5% xylene cyanol FF], heated at 
45 °C for 2 min, and subjected to electrophoresis using 1% agarose gels in 40 mM Tris-
acetate (pH 8.3) and 2 mM EDTA containing 0.5 μg/mL ethidium bromide. DNA bands 
were visualized by UV light and quantified using an Alpha Innotech digital imaging 
system. Double-stranded DNA cleavage was monitored by the conversion of negatively 
supercoiled plasmid to linear molecules. In some cases, EcoRI was used as a control for 
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double-strand cleavage (100%) and etoposide was used as positive control as an 
interfacial topoisomerase IIα poison. 
 
Enzyme-linked DNA Cleavage Controls 
DNA cleavage reactions were carried out in the presence of 0–1000 µM GE-1 or 
GE-2 or 100 µM etoposide. Unless stated otherwise, compounds were added last to 
reaction mixtures. In reactions that determined whether DNA cleavage by human 
topoisomerase IIα was reversible, 2 μL of 250 mM EDTA was added to samples prior to 
treatment with SDS. To determine whether cleaved DNA was protein-linked, proteinase 
K treatment was omitted. 
 
Oxidation-Reduction DNA Cleavage 
 To determine whether cleaved DNA was protein-linked, proteinase K treatment 
was omitted. To examine the effects of a reducing agent (DTT) or oxidizing agent 
[(K3Fe(CN)6] on the actions of 250 µM GE-1 or GE-2  against topoisomerase IIα, 250 
µM DTT or 50 µM K3Fe(CN)6 (final concentration) was incubated with the compounds 
for 10 min before their addition to DNA cleavage reaction mixtures.  
 
DNA Cleavage Site Utilization  
DNA cleavage sites were mapped using the procedure of Hawtin et al.
209
 pBR322 
DNA was linearized by treatment with HindIII, and terminal 5’-phosphates were 
removed and replaced with [
32
P]phosphate by treatment with calf intestinal alkaline 
phosphatase followed by T4 polynucleotide kinase and [-32P]ATP. The labeled DNA 
47 
was digested using EcoRI, and the 4330 bp singly-end-[
32
P] labeled fragment was 
purified from the short EcoRI-HindIII fragment by passage through a CHROMA 
SPIN+TE-100 column (Clontech).  
 Reaction mixtures contained 4 nM [
32
P]-labeled DNA substrate and 44 nM human 
topoisomerase IIα in 50 µL of DNA cleavage buffer. Assays were carried out in the 
absence of compound, or in the presence of 10 µM etoposide or 0-1000 µM GE-1 or GE-
2. Reactions were initiated by the addition of the topoisomerase IIα and were incubated at 
37 °C for 1 min. DNA cleavage intermediates were trapped by addition of 5 µL of 5% 
SDS, followed by 3.75 µL of 250 mM EDTA (pH 8.0). Proteinase K (5 µL of a 0.8 
mg/mL solution) was added and incubated at 45 °C for 30 min to digest the 
topoisomerase IIα. DNA products were precipitated in 100% ethanol and 3 M NaOAc, 
washed in 70% ethanol, dried, and resuspended in 6 µL of 40% formamide, 10 mM 
NaOH, 0.02% xylene cyanol FF, and 0.02% bromophenol blue. Samples were subjected 
to electrophoresis in a 6% denaturing polyacrylamide-sequencing gel in 100 mM Tris-
borate (pH 8.3), and 2 mM EDTA. The gel was dried and exposed to an imaging screen 
(Bio-Rad). [
32
P]-labeled DNA cleavage products were analyzed on a Pharos Molecular 
Imager FX (Bio-Rad). 
 
Persistence of Cleavage Complexes  
The persistence of topoisomerase IIα-DNA cleavage complexes was determined 
using the procedure of Gentry et al.
210
 Initial reactions contained 50 nM DNA and 550 
nM topoisomerase IIα in a total of 20 µL of DNA cleavage buffer. Reactions were carried 
out in the absence or presence of 250 µM GE-2. Reactions were incubated at 37 ºC for 6 
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min and then diluted 20–fold with 37 ºC DNA cleavage buffer. Aliquots (20 µL) were 
removed at times ranging from 0–24 h, and DNA cleavage was stopped by the addition of 
2 µL of 5% SDS followed by 2 µL of 250 mM EDTA (pH 8.0). Samples were processed 
as described above for plasmid cleavage assays. The persistence of cleavage complexes 
was monitored by the maintenance of the linear reaction product over time. 
 
Decatenation of Kinetoplast DNA 
 Decatenation assays were carried out using the procedure of Miller et al.
211
 
Reaction mixtures contained 0.2 µg of kinetoplast DNA (kDNA) from Crithidia 
fasciculate and 75 nM human topoisomerase IIα in a final volume of 20 µL of 50 mM 
Tris-Cl, pH 8.0, 120 mM KCl, 10 mM MgCl2, 0.5 mM ATP, 0.5 mM dithiothreitol.
212
 
Reactions were carried out in the presence of 0-5 mM ellipticine, ET-1, or ET-2. 
Mixtures were incubated for 15 min at 37 °C and terminated with 5% sarkosyl, 0.0025% 
bromophenol blue, and 25% glycerol. Samples were mixed with 2 µL of agarose loading 
dye [60% sucrose in 10 mM Tris-HCl pH 7.9, 0.5% bromophenol blue, and 0.5% xylene 
cyanol FF], heated for 2 min at 45 °C, and subjected to electrophoresis using 1% agarose 
gels in 40 mM Tris-borate, pH 8.3 and 2 mM EDTA containing 0.5 μg/mL ethidium 
bromide. DNA bands were visualized by UV light. DNA decatenation was monitored by 
the conversion of large catenated networks that remained at the origin to minicircles. 
 
DNA Intercalation 
 DNA intercalation reactions were carried out using the protocol of Fortune et 
al.
213
 Human DNA topoisomerase I (0.5 U) and 300 ng of relaxed pBR322 were 
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incubated in 10 mM Tris-HCl, pH 7.5, 10 mM KCl, 2 mM MgCl2, 0.02 mM EDTA, 0.1 
mM dithiothreitol, and 6 µg/ml bovine serum albumin in a final volume of 20 µL. 
Reactions were carried out in the presence of 0-25 µM ellipticine, ET-1, or ET-2. 
Ethidium bromide (10 µM), a well-characterized intercalator, was used as positive 
control, and etoposide (250 µM), a non-intercalative topoisomerase II poison, was used 
as a negative control. Mixtures were incubated for 15 min at 37 °C, and reactions were 
stopped by the addition of 3 μL of stop solution (0.77% SDS 77.5 mM EDTA, pH 8.0). 
Samples were extracted using 20 µL of phenol:chloroform:isoamyl alcohol (25:24:1), and 
the aqueous layer was mixed with 2 µL of agarose loading dye and heated for 5 min at 
45 °C. Intercalation products were subjected to electrophoresis in a 1% agarose gel in 100 
mM Tris-borate and 2 mM EDTA. Gels were stained for 30 min using 0.5 μg/mL 
ethidium bromide, rinsed in deionized water, and DNA bands were visualized as 
described above. DNA intercalation was monitored by the conversion of relaxed to 
supercoiled plasmid molecules. 
 
Binding of Plasmid DNA 
 DNA binding reactions were carried out using the procedure of Osheroff.
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Reaction mixtures contained 10 nM negatively supercoiled pBR322 DNA and 0-550 nM 
human topoisomerase IIα in a final volume of 20 µL of 10 mM Tris-HCl, pH 7.9, 5 mM 
MgCl2, 100 mM KCl, 0.1 mM EDTA, and 2.5% (v/v) glycerol. Mixtures were incubated 
for 6 min at 37 °C in the absence or presence of 25 µM ET-1 or 25 µM ET-2. Enzyme-
DNA samples were mixed with 2 µL of agarose loading dye and subjected to 
electrophoresis using 1% agarose gels in 40 mM Tris-acetate, pH 8.3 and 2 mM EDTA. 
50 
Gels were stained for 30 min using 0.5 μg/mL ethidium bromide, rinsed in deionized 
water, and DNA was visualized as described above. Enzyme-DNA binding was 
monitored by the shift of the DNA from the position of negatively supercoiled [(-)SC] 
plasmid to the origin. 
 
Covalent Adduction 
 Reaction mixtures contained 110 nM human topoisomerase IIα in buffer DNA 
cleavage buffer. Assays were carried out in the absence of compound, or in the presence 
of 10 µM hydroxytyrosol plus 10 µM K3Fe(CN)6. Reactions were incubated at 4 °C for 5 
min, followed by an incubation at 37 °C for 5 min. The samples were then acid 
precipitated using trichloroacetic acid (TCA) precipitation with an acetone wash in 
preparation for LC MS/MS. 215 Samples were precipitated by adding TCA to a final 
concentration of 25% and incubating at -20 °C for 20 min. Samples were centrifuged at 
13000 rpm for 20 min and the supernatant was aspirated. Samples were washed in ice-
cold 95% acetone (twice) by addition of 95% acetone, gently vortexing, and incubation at 
-20 °C for 20 min. Samples were air-dried and stored at -80 °C until processed. The 
samples were processed by the Vanderbilt MSRC proteomics laboratory using Liquid 
Chromatography-Mass Spectrometry/Mass Spectrometry. Mass spectrometry results 
were analyzed using the Skyline 3.5 program. (XXX)  
 
Site-directed Mutagenesis 
  Using the modified YEpWob6 vector containing the wild-type human 
topoisomerase IIα gene and a C-terminal c-myc and 6XHis tag, mutations in the 6XHis-
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tagged gene were generated by using a QuikChange Lightning Site-Directed Mutagenesis 
Kit (Agilent).
201
 The primer pairs listed below were used as templates to mutate human 
topoisomerase II at the sites: C427A, C455A, C427A/C455A (Dbl mt), and C104A 
C427A_Fwd 5’-gcccaagtccagttaaacaagaaggcttcagctgtaaaacataatagaat 
C427A_Rev 5’-attctattatgttttacagctgaagccttcttgtttaactggacttgggc 
C455A_Fwd 5’-gccgaaactccactgaggctacgcttatcctgactg  
C455A_Rev 5’-cagtcaggataagcgtagcctcagtggagtttcggc 
C104A_Fwd 5’-acaaagggacccaaaaatgtctgctattagagtcacaattgatccg 
C104A_Rev 5’-cggatcaattgtgactctaatagcagacatttttgggtccctttgt 
The mutated positions are underlined. The mutated genes encoding the C427A and 
C455A mutations were sequenced for accuracy using the primer 5’-cccaagagctttggatcaac. 
The mutated gene encoding the C104A mutation was sequenced for accuracy using the 
primer 5’-gtggaattagtgacccagcaa. 
    
Expression of Human Topoisomerase IIα and Mutants 
 Human topoisomerase IIα wild-type, mutant C427A, C455A, C427A/C455A, or 
C104A DNA was transformed into yeast cells and expressed as previously described.
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Briefly, the cells were grown at 30 °C, shaking, in ura
-
 minimal medium, supplemented 
with 2% (w/v) glucose, 3% (v/v) glycerol, and 2% (w/v) lactic acid. At log phase the 
culture was diluted 100-fold into the same medium without glucose. Cells were induced 
at an OD600 of 0.3-0.4 with galactose (2% (w/v) final concentration). Cells were 
harvested after 24 h, washed with autoclaved water, and then with lysis buffer [50 mM 
Tris-HCl (pH 7.7), 10% (w/v) glycerol, 1 mM EDTA, 1 mM EGTA] plus 25 mM NaF, 1 
52 
mM Na2S2O5, 1 mM BME and 1 mM PMSF]. Cells were then resuspended in 2 ml of 
lysis buffer/g of wet-packed cells, frozen rapidly in liquid nitrogen, and stored at -80 °C. 
 
Purification of 6XHis-Human Topoisomerase IIα and Mutants 
In preparation for protein purification, the harvested cells were quickly thawed 
under running lukewarm water and lysed using Y-PER Plus (Thermo-Scientific) at 2 ml/g 
containing 500 mM NaCl, 1 mM PMSF and protease inhibitors (1 µg/ml leupeptin and 1 
µg/ml pepstatin A), while shaking at RT for 15 min. Unless otherwise noted, the 
following purification steps were carried out at 4 °C.  The lysate was cleared by 
centrifugation at 14 000 rpm using a JA 25.50 rotor for 10 min. Imidazole was then added 
to the cleared lysate to the final concentration of 5 mM and the lysate was subjected to 
batch binding to 2 mL of Ni-NTA agarose beads (Qiagen) slurry for 1 hr. After binding, 
the resin was harvested at 700 rpm in a Sorvall H1000B rotor (Dupoint Instruments) for 3 
min. The nickel resin was then washed in 14 ml of wash buffer 1 [20 mM Tris-HCl (pH 
7.9), 1 M NaCl, 30 mM imidazole, 1 mM BME, 1 mM PMSF, and protease inhibitors] 
for 10 min followed by 30 ml of wash buffer 2 [20 mM Tris-HCl (pH 7.9), 0.5 M NaCl, 
30 mM imidazole, 1 mM BME, 1 mM PMSF, and protease inhibitors] for 10 min. 5 ml of 
wash buffer 2 was added to the protein bound-nickel resin and transferred into a 1 x 10 
cm Econo column (BioRad), while the extra wash buffer was removed by gravity. The 
enzyme was eluted by gravity with 5 mL of elution buffer [20 mM Tris-HCl (pH 7.9), 0.5 
mM NaCl, 300 mM imidazole, 1 mM BME, 1 mM PMSF, and protease inhibitors]. 1 mL 
fractions were collected and assessed for protein by SDS-PAGE and fractions 1-4 were 
pooled after protein presence verification. 
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The protein was further purified and concentrated by a P11 phosphocellulose (P-
cell) column (Whatman) equilibrated in P-200 buffer [50 mM Tris-HCl (pH 7.7), 200 
mM KCl, 40% (w/v) glycerol, 0.1 mM EDTA, 0.5 mM DTT]. The protein collected from 
the eluted fractions was diluted with P200 buffer until the conductivity of the sample 
buffer was below that of the P-cell buffer. The protein sample was then loaded onto a 1 
ml P-cell column, washed with 1 column volume of P200 buffer and eluted by gravity 
with 3 column volumes of P750 buffer [50 mM Tris-HCl (pH 7.7), 750 mM KCl, 40% 
(w/v) glycerol, 0.1 mM EDTA, 0.5 mM DTT] in 3 drop fractions. The fractions were the 
assessed for protein presence by Bradford analysis and fractions containing protein were 
pooled.  
 Bradford analysis was used to determine the protein concentrations. A 50 kDa 
MWCO Amicon Ultra concentrator was used to further concentrate the protein at 2500 
rpm in a Sorvall H1000B rotor set at 4 °C. Homogeneity of the topoisomerase II 
preparations was determined by SDS-polyacrylamide gel analysis of a Mini-Protean TGX 
7.5% polyacrylamide gel (Bio-Rad) after staining with Coomassie dye. Fractions 
containing topoisomerase II enzyme were pooled and stored in liquid nitrogen for later 
use. Wild-type His-tagged topoisomerase IIα was prepared parallel to the mutant 
enzymes. 
 
Enzyme activity 
 DNA cleavage reactions were performed similar to the plasmid cleavage methods 
provided above. Reaction mixtures contained 0-300 nM His-tagged human topoisomerase 
IIα and mutants and 10 nM negatively supercoiled pBR322 DNA in a total of 20 µL of 
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cleavage buffer. DNA cleavage reaction mixtures were incubated at 37 °C for 6 min, and 
the enzyme-DNA cleavage complexes were stopped, processed, and visualized as 
described above for plasmid cleavage assays.  
 DNA relaxation assays were based on the procedure of Fortune and Osheroff. 208 
Reaction mixtures contained 0.02-110 nM  enzyme, 5 nM negatively supercoiled 
pBR322 DNA and 1 mM ATP in a total of 20 µl of relaxation buffer (10 mM Tris-HCl 
(pH 7.9), 0.1 mM EDTA, 175 mM KCl, 5 mM MgCl2, and 2.5% glycerol). Samples 
were incubated at 37 °C for 15 min, and DNA relaxation was terminated by the addition 
of 3 µl of stop solution [0.77% SDS, 77 mM EDTA (pH 8.0)]. Samples were mixed with 
2 µl of agarose gel loading buffer [60% sucrose in 10 mM Tris-HCl (pH 7.9)], heated at 
45 °C for 5 min, and subjected to electrophoresis in a 1% agarose gel in 100 mM Tris 
borate (pH 8.3), 2 mM EDTA. The gel was stained for 30 min with gentle shaking in 200 
ml of TBE containing 1 µg/ml EtBr and rinsed in deionized water. DNA bands were 
visualized with ultraviolet light. DNA relaxation activity was monitored by the 
conversion of negatively supercoiled DNA to relaxed DNA. His-tagged human 
topoisomerase IIα was used as an enzyme control. 
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CHAPTER III  
 
EFFECTS OF OLIVE METABOLITES ON DNA CLEAVAGE MEDIATED BY 
HUMAN TYPE II TOPOISOMERASES 
 
Introduction 
 
 A broad spectrum of anticancer drugs comes directly from natural sources or is 
derived from natural products. Many of these compounds are botanical in nature. Plants 
have been used for culinary and medicinal purposes for millennia. The Mediterranean 
basin is home to a biologically diverse plant biome and is a particularly rich source of 
botanicals with medicinal properties. 
93,216,217
 Many of these have been used in traditional 
Bedouin and Israeli medicine since antiquity. Phytochemicals derived from 
Mediterranean plant species have been shown to provide a variety of health benefits and 
display anti-inflammatory, anticancer, cardioprotective, and chemopreventative 
properties.
93,216,217
 
 In an effort to discover novel phytochemicals with activity against human type II 
topoisomerases, we carried out a blind screen of a library of 341 Mediterranean plant 
extracts to determine whether any of them increased levels of DNA cleavage mediated by 
topoisomerase IIα. Species in the library were primarily from arid lands or the Tel Aviv 
University Botanical Garden and included plants used in traditional Bedouin 
56 
medicine.
204,205
  An extract from Phillyrea latifolia L., a member of the Oleaceae family 
of olive trees, displayed high activity against the human enzyme. Using a metabolomics 
approach, we identified several polyphenols as potential candidates for topoisomerase II 
poisons. From these compounds, we determined that hydroxytyrosol, oleuropein, and 
verbascoside were covalent poisons. The activities of these compounds were accentuated 
under oxidizing conditions. Finally, commercial olive leaf extract and extra virgin olive 
oils also poisoned human topoisomerase IIα. 
 
Results and Discussion 
 
An Extract of P. latifolia L. Enhances DNA Cleavage Mediated by Human 
Topoisomerase IIα.  
  A number of dietary polyphenols and isothiocyanates with chemopreventive or 
anticancer properties have been found to be topoisomerase II poisons.
57,58,105,112,145-
147,154,164,218
 In all of the above cases, studies were initiated by examining the effects of 
purified compounds on the activity of the type II enzyme. In order to take a broader and 
less biased approach to the discovery of naturally occurring topoisomerase II poisons, a 
library of 341 Mediterranean plant extracts was screened for its effects on DNA cleavage 
mediated by human topoisomerase IIα. Extract #263 prepared from the leaves of P. 
latifolia L., a member of the Oleaceae olive tree family, displayed high activity against 
topoisomerase IIα and increased levels of DNA cleavage nearly 8–fold at 200 µg/mL 
(Figure 13).  
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Figure 13. Effects of P. latifolia L. on DNA cleavage activities mediated by human 
topoisomerase II. The effects of plant extract #263 (P. latifolia L.) on the cleavage of 
negatively supercoiled DNA by topoisomerase IIα were determined in the absence (filled 
circles) or presence (open circles) of 100 µM DTT. DNA cleavage levels were calculated 
relative to a control reaction that contained no extract. Error bars represent the standard 
deviation of at least three independent experiments. 
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  Previous metabolomic studies on P. latifolia L. leaves indicate the presence of 
several bioflavonoid derivatives, including glucosides and rutinosides of apigenin, 
quercetin, and luteolin.
219,220
 Although the three unmodified bioflavonoids are known 
interfacial topoisomerase II poisons, it is not known whether the above glycoside 
derivatives retain activity within the soluble extract.
146,154
 Therefore, to determine 
whether these bioflavonoid glycosides (or other potential interfacial poisons) represented 
the topoisomerase II-active compounds in P. latifolia L., the extract was assayed for 
activity in the presence of a reducing agent, dithiothreitol (DTT). As seen in Figure 13, 
the extract lost its activity under reducing conditions. This finding suggests that the active 
metabolites present in the P. latifolia L. extract are covalent poisons, rather than 
bioflavonoid-based interfacial poisons.
103
 
 
 Olive Metabolites Poison Human Type II Topoisomerases 
 Several phenolic compounds with antioxidant activity are abundant in P. latifolia 
L. and have the potential to act as covalent topoisomerase II poisons.
57,219,220
 Among 
these metabolites are hydroxytyrosol, oleuropein, verbascoside, tyrosol, and caffeic acid. 
Oleuropein contains an esterified hydroxytyrosol component and verbascoside contains 
esterified hydroxytyrosol and caffeic acid components. Tyrosol is a breakdown product 
of hydroxytyrosol. The structures of these compounds are shown in Figure 14. 
  To determine whether any of the above P. latifolia L. metabolites contributed to 
the activity of the extract against human topoisomerase IIα, the ability of individual 
compounds to enhance enzyme-mediated DNA cleavage was examined (Figure 15). 
Hydroxytyrosol, oleuropein, and verbascoside all increased levels of DNA cleavage more  
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Figure 14. Structures of olive metabolites. Polyphenols present in P. latifolia L. and 
other olive species, including hydroxytyrosol, oleuropein, verbascoside, caffeic acid, and 
tyrosol are shown. Hydroxytyrosol (red) is a component of oleuropein and verbascoside, 
and caffeic acid (blue) is a component of verbascoside. 
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Figure 15. Effects of olive metabolites on DNA cleavage activities mediated by 
human topoisomerase II. A) The effects of the hydroxytyrosol (HT; red), oleuropein 
(OE; green), and verbascoside (VERB; purple), caffeic acid (CA; blue), and tyrosol (TY; 
black) on DNA cleavage mediated by topoisomerase IIα are shown. DNA cleavage levels 
were calculated relative to a control reaction that contained no metabolite. Error bars 
represent standard deviations for three independent experiments. B) DNA cleavage 
induced by hydroxytyrosol (top), oleuropein (middle), or verbascoside (bottom) is 
reversible and protein-linked. Ethidium bromide-stained agarose gels are shown. Assay 
mixtures contained DNA with olive metabolites in the absence of enzyme (-TII), 
topoisomerase IIα with DNA in the absence of olive metabolites (TII), or complete 
reactions stopped with SDS prior to the addition of EDTA (SDS). To determine whether 
the reaction was reversible, EDTA was added prior to SDS (EDTA). To determine 
whether the cleaved DNA was protein-linked, proteinase K treatment was omitted (-
ProK). The mobility of negatively supercoiled DNA (form I; FI), nicked circular plasmid 
(form II; FII), and linear molecules (form III; FIII) are indicated. Gels are representative 
of three independent experiments. 
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than 3–fold. Conversely, tyrosol and caffeic acid displayed virtually no activity against 
the human type II enzyme. 
  To ensure that the observed DNA cleavage enhancement was mediated by the 
type II enzyme, several control experiments were performed (Figure 15B). No DNA 
scission was seen in the presence of hydroxytyrosol (top), oleuropein (middle), or 
verbascoside (bottom) when the type II enzyme was left out of reactions. Furthermore, 
enzyme-mediated DNA cleavage induced by the olive metabolites was reversed when the 
active site Mg
2+
 ions were chelated with EDTA prior to trapping cleavage complexes 
with SDS. This reversibility is not consistent with an enzyme-independent reaction. 
Finally, cleaved plasmid products were covalently linked to topoisomerase II. In the 
absence of proteinase K the linear DNA band disappeared and was replaced by a band 
that remained at the origin of the gel. These results demonstrate that the DNA cleavage 
observed in the presence of the metabolites is mediated by topoisomerase IIα. 
  Although hydroxytyrosol, oleuropein, and verbascoside are all polyphenols, it is 
likely that they would have to cycle through a quinone form in order to become reactive 
toward topoisomerase IIα.57,221 A previous study found that the buffer used for 
topoisomerase II-mediated DNA cleavage reactions does not readily support redox 
cycling.
58
 This is consistent with the high concentrations of metabolites required to 
enhance DNA cleavage. Therefore, the effect of an oxidant, K3Fe(CN)6, on the activity of 
hydroxytyrosol, oleuropein, and verbascoside toward topoisomerase IIα was examined 
(Figure 16A). This oxidant has little effect on levels of baseline DNA cleavage mediated 
by topoisomerase IIα, but had a dramatic effect on the activity of the metabolites.  DNA 
cleavage induced by the metabolites plateaued at 10 µM K3Fe(CN)6 (Figure 16A, left).  
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Figure 16. Effects of oxidant on human topoisomerase II-mediated DNA cleavage 
induced by olive metabolites. A) The effects of an oxidant, K3Fe(CN)6, on DNA 
cleavage mediated by topoisomerase IIα were determined in the presence of 100 µM 
olive metabolites [hydroxytyrosol (HT; red), oleuropein (OE; green), verbascoside 
(VERB; purple), caffeic acid (CA; blue), and tyrosol (TY; black)] or in the absence of 
metabolite (TII; gray) (left). The effects of olive leaf metabolites on DNA cleavage were 
determined in the presence of 10 µM K3Fe(CN)6 (right). B) The effects of olive 
metabolites on DNA cleavage mediated by human topoisomerase IIβ were determined in 
the presence of 10 µM K3Fe(CN)6. DNA cleavage levels were calculated relative to a 
control reaction that contained no metabolite and no oxidant. Error bars represent 
standard deviations for three independent experiments. 
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Consequently, this concentration was used for all subsequent reactions that contained the 
oxidant.  
  The presence of K3Fe(CN)6 increased the potency of hydroxytyrosol, oleuropein, 
and verbascoside toward topoisomerase IIα as much as 100–fold (Figure 16A, right). 
Whereas 250 µM to 1 mM metabolite was required to increase DNA cleavage between 
3– to 4–fold in the absence of oxidant (see Figure 15A), a similar DNA cleavage increase 
in reactions that contained K3Fe(CN)6 required only 5-10 µM metabolite. Despite the 
presence of the oxidant, neither tyrosol nor caffeic acid displayed any significant ability 
to poison topoisomerase IIα. 
  The effects of hydroxytyrosol, oleuropein, and verbascoside on DNA cleavage 
mediated by human topoisomerase IIβ also were assessed (Figure 16B). In the presence 
of oxidant, all three polyphenols were potent topoisomerase II poisons and increased 
DNA cleavage >8–fold at a metabolite concentration of 10 µM. The higher relative 
activity of olive metabolites against topoisomerase IIβ as compared to IIα primarily 
reflects lower baseline levels of DNA cleavage observed with the β isoform in the 
absence of poisons. 
  The effects of hydroxytyrosol, oleuropein, and verbascoside (10 µM) on DNA 
cleavage site utilization by human topoisomerase IIα were determined in the presence of 
oxidant (Figure 17). Similar sites of cleavage were induced by all three metabolites. 
Several of the sites induced by the metabolite were the same as those induced by 
etoposide, although some sites were utilized to a different extent. Distinct sites also were 
observed in the presence of the metabolites compared to the drug. Similar DNA cleavage 
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Figure 17. Effects of olive metabolites on DNA cleavage site utilization by human 
topoisomerase IIα. An autoradiogram of a polyacrylamide gel is shown. Reaction 
mixtures contained no enzyme (DNA), enzyme in the absence of metabolite (TII), or 
enzyme in the presence of 10 μM hydroxytyrosol (HT), oleuropein (OE), or verbascoside 
(VERB) in the presence of 10 μM K3Fe(CN)6. A control DNA cleavage reaction that 
contained 20 μM etoposide also is shown. The autoradiogram is representative of three 
independent experiments. 
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 maps were generated in the presence of 1 mM metabolites in the absence of oxidant 
(data not shown). 
  Although etoposide and other interfacial poisons increase topoisomerase II-
mediated DNA scission primarily by inhibiting the ability of the enzyme to ligate cleaved 
molecules, covalent poisons often induce DNA cleavage without displaying large effects 
on rates of ligation.
19,57,99,103
 As seen in Figure 18A, hydroxytyrosol, oleuropein, and 
verbascoside had relatively little effect on DNA ligation mediated by topoisomerase IIα 
in the absence or presence of oxidant. In contrast, no ligation was observed in the 
presence of etoposide. These findings are consistent with the olive metabolites acting as 
covalent poisons and suggest that they may increase levels of DNA cleavage complexes 
primarily by enhancing the forward rates of DNA cleavage.  
  Because covalent poisons adduct topoisomerase II, they cannot dissociate from 
the enzyme.
19,57,84
 Thus, once DNA cleavage complexes are formed in the presence of 
covalent poisons, they can remain intact for hours.
112
 To address the stability of cleavage 
complexes formed in the presence of hydroxytyrosol, oleuropein, or verbascoside, DNA 
cleavage complexes were diluted 20–fold and their decay was monitored (Figure 18B). In 
the absence of poisons, topoisomerase IIα-DNA cleavage complexes undergo a rapid 
decay and display a half-life less than 1 min.
112
 In contrast, cleavage complexes formed 
in the presence of 10 µM metabolite + oxidant or 1 mM metabolite without oxidant were 
extremely stable and remained intact for at least 24 h. 
  
66 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Effects of olive leaf metabolites on human topoisomerase II-mediated 
DNA cleavage complex stability. A) The ability of human topoisomerase IIα to ligate 
cleaved DNA is shown. Reactions (20 s) were carried out in the presence of no 
metabolite (TII; gray), hydroxytyrosol (HT; red), oleuropein (OE; green), verbascoside 
(VERB; purple) or 100 µM etoposide (ETOP; black). Reactions contained 1 mM 
metabolite and no oxidant (left) or 10 µM metabolite in the presence of 10 µM 
K3Fe(CN)6 (right). B) The effects of olive metabolites on the persistence of 
topoisomerase IIα-DNA cleavage complexes in the absence or presence of oxidant are 
shown. Assays were carried out in the presence of 1 mM metabolite (open circles) or 10 
µM metabolite + 10 µM K3Fe(CN)6 (closed circles). Colors are as described above. For 
both the ligation and persistence reactions, DNA cleavage levels at time zero were set to 
100% to allow a direct comparison. Error bars represent the standard deviation of at least 
three independent experiments. 
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Hydroxytyrosol, Oleuropein, and Verbascoside are Covalent Topoisomerase IIα Poisons. 
  The above results, together with the finding that P. latifolia L. extracts lost their 
ability to poison topoisomerase IIα in the presence of a reducing agent, strongly suggest 
that hydroxytyrosol, oleuropein, and verbascoside are covalent topoisomerase II poisons. 
Therefore, a series of experiments was carried out in order to address the basis for the 
actions of the olive metabolites against topoisomerase IIα. 
  First, if the olive metabolites are covalent poisons, their ability to cycle through 
an activated quinone form should be critical to their activity.
57,58,147
 Therefore, in order to 
inhibit redox cycling, 1 mM hydroxytyrosol, oleuropein, and verbascoside were 
incubated with 100 µM DTT prior to their addition to DNA cleavage reaction mixtures. 
As seen in Figure 19, treatment with the reducing agent abrogated the activity of the olive 
metabolites (open bars). Levels of DNA scission were reduced to baseline cleavage 
generated by the type II enzyme.  
  Second, once covalent poisons have adducted topoisomerase II, their redox state 
no longer affects their activity.
19,57,103,104
 Thus, the addition of reducing agents to reaction 
mixtures after DNA cleavage−ligation equilibria have been established in the presence of 
a covalent poison should not reverse the cleavage enhancement. As seen in Figure 19 
(stippled bars), the addition of DTT after cleavage complexes had been formed in the 
presence of hydroxytyrosol, oleuropein, or verbascoside had no significant effect on 
levels of DNA scission mediated by the type II enzyme. 
  Third, to further examine the requirement for the conversion of olive metabolites 
to an activated quinone, one or both of the hydroxyl moieties of hydroxytyrosol were 
converted to methoxyl groups (4-hydroxy-3-methoxyphenylethanol and 3,4-dimethoxy- 
68 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Ability of olive metabolites to enhance DNA cleavage as covalent 
topoisomerase II poisons.  A) Effects of DTT on the ability of olive metabolites to 
enhance DNA cleavage mediated by topoisomerase IIα. DNA cleavage reactions were 
carried out in the absence of DTT (filled bars, No DTT), in the presence of 100 μM DTT 
that was added after the cleavage–ligation equilibrium was established (stippled bars, 
Post DTT), or in the presence of 100 μM DTT that was added at the start of the reaction 
(open bars, Pre DTT). Reaction mixtures contained 1 mM hydroxytyrosol (HT; red), 
oleuropein (OE; green), or verbascoside (VERB; purple). DNA cleavage levels were 
calculated relative to a control reaction that contained no metabolite. B) Effects of 3,4-
dimethoxyphenylethanol and 4-hydroxy-3-methoxyphenylethanol on topoisomerase IIα-
mediated DNA cleavage. The effects of 500 µM 3,4-dimethoxyphenylethanol (black bar) 
or 4-hydroxy-3-methoxyphenylethanol (white bar) on the cleavage of negatively 
supercoiled plasmid DNA by topoisomerase IIα were determined in the presence 10 µM 
K3Fe(CN)6. Reactions that contained no compounds are shown in gray. DNA cleavage 
levels were calculated relative to a control reaction that contained no compounds or 
oxidant. In all cases, error bars represent standard deviations for three independent 
experiments. 
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phenylethanol, respectively). The loss of the hydroxyl groups should prevent these 
compounds from undergoing redox cycling.
58
 Even in the presence of an oxidant, neither 
compound increased DNA cleavage mediated by topoisomerase IIα above baseline levels 
(Figure 19). These findings provide further evidence that olive metabolites require redox 
cycling in order to enhance topoisomerase II-mediated DNA cleavage. 
 Fourth, although covalent poisons enhance DNA scission when added to cleavage 
complexes, they irreversibly inhibit topoisomerase IIα when incubated with the enzyme 
prior to the addition of DNA. This inhibition is a hallmark characteristic of covalent 
poisons and is not seen with interfacial poisons.
57,84,102,103,114
 Hydroxytyrosol, oleuropein, 
and verbascoside (1 mM) all inhibited the DNA cleavage activity of topoisomerase IIα 
when added to reaction mixtures prior to the addition of DNA (Figure 20, left). Rates of 
enzyme inactivation were increased by the presence of K3Fe(CN)6 (right), despite the fact 
that the concentration of the olive metabolites (10 µM) was 100–fold lower than used in 
the absence of the oxidant. 
  Fifth, covalent topoisomerase II poisons are believed to enhance enzyme-
mediated DNA cleavage, at least in part, by affecting the N-terminal protein clamp.
102,111
 
Consequently, they require the presence of the N-terminal domain (but not the C-terminal 
domain) of the protein in order to exert their effects. Interfacial topoisomerase II poisons, 
such as etoposide, require neither the N- nor the C-terminal protein domains, and enhance 
DNA cleavage even in a protein construct that contains only the catalytic core.
98
 In order 
to determine which protein domains are required for hydroxytyrosol, oleuropein, and 
verbascoside to poison topoisomerase II, their effects on DNA cleavage mediated by 
topoisomerase IIα constructs lacking the C-terminal domain or both the N- and C- 
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Figure 20. Ability of olive metabolites to inhibit topoisomerase IIα activity prior to 
DNA addition. The effects of hydroxytyrosol (HT; red), oleuropein (OE; green), and 
verbascoside (VERB; purple) are shown. Metabolites were incubated with the human 
enzyme in the absence of oxidant (1 mM metabolite, closed circles, left), or in the 
presence of 10 µM K3Fe(CN)6 (10 µM metabolite, open circles, right). DNA cleavage 
levels were calculated relative to a control reaction in which the metabolite was added 
after the addition of DNA to assay mixtures. Error bars represent the standard deviation 
of at least three independent experiments. 
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terminal domains (catalytic core) were assessed (Figure 21). Etoposide displayed high 
activity against both constructs. Although, the olive metabolites retained activity against 
Top2α∆1175 (Panel A), they lost their ability to enhance DNA cleavage in absence of the 
N-terminal domain (catalytic core, Panel B). The presence of oxidant did not alter this 
latter result. 
 Finally, human topoisomerase IIα was treated with hydroxytyrosol and the 
resulting peptides generated by tryptic digestion were analyzed by MALDI mass 
spectrometry (Figure 22). A change in a peptide containing cysteine 104, positioned in 
the ATPase domain of the enzyme, was observed following treatment with 
hydroxytyrosol. No significant changes were observed in peptides that did not contain 
cysteine residues. Taken together, the above findings provide strong evidence that 
hydroxytyrosol, oleuropein, and verbascoside are covalent topoisomerase II poisons. 
 
 Extracts from Olive Tree Species Enhance DNA Cleavage Mediated by Topoisomerase 
IIα  
  Hydroxytyrosol, oleuropein, and verbascoside (and other polyphenols) have been 
reported in several members of the olive tree family.
222-225
 Therefore, it is possible that 
other olive tree species may also produce topoisomerase II poisons. 
 Eleven different species of plants from the Oleaceae family grow in Israel. Leaf, 
bark, and fruit samples were harvested from these species and 36 extracts were prepared 
and tested for activity against human topoisomerase IIα (Figure 23). A number of extracts 
(at 2 mg/mL) increased enzyme-mediated DNA cleavage. Activity against topoisomerase 
IIα was observed across multiple species and was found in the leaf, bark, and fruit of the  
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Figure 21. Requirements of topoisomerase IIα domains for olive metabolites to 
enhance DNA cleavage. The effects of olive metabolites on DNA cleavage mediated by 
topoisomerase IIα lacking the C-terminal domain (∆1175) or both the C-terminal and N-
terminal domains (Catalytic core) are shown in panels A and B, respectively. DNA 
cleavage reactions were carried out using 1 mM metabolites [hydroxytyrosol (HT; red), 
oleuropein (OE; green), or verbascoside (VERB; purple)] in the absence of oxidant 
(closed bars) or 10 µM metabolite in the presence of 10 µM K3Fe(CN)6. Results with no 
metabolites (TII, gray) or 100 µM etoposide (ETOP, black) in the absence or presence of 
oxidant are shown as controls. DNA cleavage levels were calculated relative to scission 
generated by restriction endonucease EcoRI, which was set to 100%. Error bars represent 
the standard deviation of at least three independent experiments. Baseline levels of DNA 
cleavage generated by the catalytic core are lower than those generated by full-length 
topoisomerase IIα.  
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Figure 22. Mass spectrometry analysis suggesting adduction within a peptide 
containing cysteine residue 104. The graph on the left depicts the presence of the 
peptide fragment (101-105) in the expected (theoretical) versus experimental samples. 
Sample 1 contained only human topoisomerase IIα, while sample 2 human topoisomerase 
IIα treated with the covalent poison hydroxytyrosol. An Idotp >0.90 is considered 
statistically significant in the Skyline data processing program. (Data analyzed in part by 
Vanderbilt Proteomics Core) The model and schematic on the right highlights the 
location of cysteine residue 104 within the N-gate.   
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Figure 23. Effects of soluble olive tree extracts on DNA cleavage mediated by 
topoisomerase IIα. Thirty-six leaf, bark, and fruit extracts were prepared from 11 
different species of olive trees that are indigenous to Israel. DNA cleavage reactions were 
carried out in the presence of 2 mg/mL extract. Abbreviations are: Olea africana (O. af), 
Olea europea (O. eu), Forsithia europaea (F. eu), Fraxinus latifolia (F. la), Fraxinus 
pennsylvanica (F. pe), Fraxinus syriaca (F. sy), Fraxinus sogdiana (F. so), Fraxinus 
angustifolia (F. an), Jasminium fruiticans (J. fr), Phillyrea latifolia (P. la), Phillyrea 
angusifolia (P. an). DNA cleavage levels were calculated relative to a control reaction 
(dashed line) that contained no extract. Error bars represent the standard deviation of at 
least three independent experiments. 
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trees. Generally, the highest levels of activity were seen in bark extracts. However, 
several fruit extracts also displayed high levels of DNA cleavage enhancement. These 
results suggest that topoisomerase II poisons are widely produced by members of the 
olive tree family. 
  To further explore the presence of topoisomerase II poisons in olive species, the 
ability of a commercial olive leaf extract (species not identified by the manufacturer) to 
enhance enzyme-mediated DNA cleavage was assessed (Figure 24). The herbal 
supplement enhanced DNA cleavage mediated by topoisomerase IIα nearly 5–fold at 20 
mg/mL. Thus, olive metabolites can poison the type II enzyme, even in more complex 
formulations intended for human consumption. 
 
Effects of Extra Virgin Olive Oils on DNA Cleavage Mediated by Topoisomerase IIα.  
  Hydroxytyrosol, oleuropein, and verbascoside all are present in the fruit of the 
olive tree and have been reported in olive oil.
222-225
 Therefore, the effects of three 
commercial extra virgin olive oils on DNA cleavage mediated by topoisomerase IIα were 
assessed. Oils were pressed from a variety of subspecies of O. europea, including 
arbosana, koroneiki, or a mixture of frantoio, moraiolo, leccino, maurino, and pendolino 
olives. Olive oils were added to DNA cleavage assay mixtures at a final concentration of 
10% by volume. 
  In the absence of an oxidant, no DNA cleavage enhancement was observed (data 
not shown). However, in the presence of 10 µM oxidant, the extra virgin olive oils 
increased DNA scission 2– to 4– fold (Figure 25, left). Because polyphenols are water 
soluble, aqueous extracts of each olive oil were tested for activity against the type II  
76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Effects of a commercial olive leaf extract on DNA cleavage mediated by 
topoisomerase IIα. The effects of a commercial olive leaf extract (Olive leaf PlusTM) on 
DNA cleavage mediated by the human type II enzyme are shown. DNA cleavage levels 
were calculated relative to a control reaction that contained no extract. Error bars 
represent the standard deviation of at least three independent experiments.
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Figure 25. Extra virgin olive oils enhance DNA cleavage mediated by topoisomerase 
IIα. The effects of extra virgin olive oils (EVOO) or an EVOO H2O extract on DNA 
cleavage mediated by the human type II enzyme are shown in panels A and B, 
respectively. Olive oils [Ultra Arbonsana (A, yellow), Ultra Koroneiki (K, green), or 
Lucini Select (L, brown)] or extracts from these oils were included in reaction mixtures at 
final concentrations of 10% (v/v) in the presence of 10 µM K3Fe(CN)6. Results for 
reactions that contained no oils or extracts, but contained oxidant (TII, gray), are shown. 
DNA cleavage levels were calculated relative to a control reaction that contained no olive 
oil or oxidant. Error bars represent the standard deviation of at least three independent 
experiments. Statistically significant differences are noted by asterisks (*p < 0.05, **p < 
0.001, ***p ≤ 0.0001).  
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enzyme (Figure 25, right). The extracts increased enzyme-mediated DNA cleavage to an 
extent that was similar to those of each individual extra virgin olive oil. Thus, olive 
products that are part of the human diet are capable of acting as topoisomerase II poisons. 
  
Conclusions 
 
 In an effort to identify natural products that function as topoisomerase II poisons, 
a library of 341 extracts from Mediterranean plants was screened for the ability to 
enhance DNA cleavage mediated by human topoisomerase IIα. An extract from P. 
latifolia L., a member of the olive tree family, displayed high activity against the human 
enzyme. Further studies led to the identification of hydroxytyrosol, oleuropein, and 
verbascoside as covalent topoisomerase II poisons. An herbal supplement from olive leaf 
extracts, as well as extra virgin olive oils pressed from a variety of O. europea subspecies, 
also enhanced DNA cleavage mediated by human topoisomerase IIα. Thus, olive 
metabolites appear to act as topoisomerase II poisons in complex formulations intended 
for human dietary consumption. 
 Hydroxytyrosol, oleuropein, and verbascoside are well-established antioxidants. 
All of them induce cell cycle arrest, display anti-proliferative effects, and show activity 
against in vivo tumor models.
226-231
 Furthermore, hydroxytyrosol is believed to have 
chemopreventative properties and currently is in clinical trials as a preventative agent for 
women at high risk for breast cancer.
232
 Olive oil is a key component of the 
79 
Mediterranean dietary pattern, and epidemiological observations indicate that this diet 
has great potential for cancer prevention.
93,223,234,235
  
 Following consumption of 25 ml of virgin olive oil, the concentration of 
hydroxytyrosol in blood is estimated to be as high ~1 µM.
236
 Thus, at least under 
oxidizing conditions, physiological levels of hydroxytyrosol are in a range at which it 
displays activity against human type II topoisomerases.  
 Although phenolic olive metabolites display complex cellular activities, it has 
been proposed that they exert at least some of their biological effects by redox-induced 
oxidation to quinones and subsequent protein adduction.
221
 The finding that 
hydroxytyrosol, oleuropein, and verbascoside are covalent topoisomerase II poisons and 
that their activity is enhanced by oxidation is consistent with this hypothesis. Results of 
the present study suggest that the ability of these olive leaf metabolites to poison 
topoisomerase II may contribute to their therapeutic properties. (See appendix for follow-
up that were performed to attempt to better understand the effects of covalent poisons at 
reactive cysteine sites) 
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CHAPTER IV  
 
INHIBITION OF HUMAN DNA TOPOISOMERASE IIα BY TWO NOVEL 
ELLIPTICINE DERIVATIVES 
 
Introduction 
 
 Ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole; C17H14N2; MW: 246.31), a 
natural product first isolated from the Australian evergreen tree, is an antineoplastic agent 
that intercalates into DNA and alters topoisomerase II activity.
100,237-244
 The compound is 
a mild poison against topoisomerase II from Drosophila and Saccharomyces 
cerevisiae.
241,242
 However, most studies report that ellipticine induces little, if any, DNA 
cleavage mediated by mammalian type II topoisomerases and inhibits enzyme activity at 
higher concentrations.
100,239-241
 In contrast to the parent compound, several ellipticine 
derivatives are potent topoisomerase II poisons in mammalian systems and display 
anticancer activity against human breast cancer and other solid tumors.
238,244,245
 
Unfortunately, these compounds induce a number of adverse effects such as xerostomia, 
weight loss, hemolysis, and renal toxicity. Moreover, the parent compound, ellipticine, 
displays poor water solubility and target specificity, and drug resistance has been 
observed upon prolonged administration.
239,246-248
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Results and Discussion 
 
   In an effort to investigate new ellipticine-based compounds for their potential as 
topoisomerase II-targeted drugs, we synthesized two novel derivatives, N-methyl-5-
demethyl ellipticine (ET-1) and 2-methyl-N-methyl-5-demethyl ellipticinium iodide (ET-
2). Ellipticine derivatives were synthesized via a novel pathway shown in Fig. 26. The 
detailed syntheses and physical and chemical characterizations of ET-1 and ET-2 are 
described in the accompanying Appendix. 
 Briefly, ET-1 and ET-2 were generated using a nine-step synthetic pathway with a 
12% overall yield (Figure 26). First, 4,9-dimethyl-9H-carbazole-3-carbaldehyde (1) was 
synthesized in five steps, according to the literature, starting from Hagemann’s ester 
(ethyl-2-methyl-4-oxocyclohex-2-enecarboxylate).
249,250
 We then generated N-methyl-5-
demethyl ellipticine (ET-1; C18H17N2I; MW: 246.3) and 2-methyl-N-methyl-5-demethyl 
ellipticinium iodide (ET-2; C17H14N2; MW: 388.2) in four subsequent steps.
251
 Aldehyde 
1 was treated with aminoacetaldehyde diethylacetal in solvent-free conditions to yield 
imine 2. The imine was reduced with sodium borohydride to produce amine 3, which was 
treated with benzene sulfonyl chloride to produce sulfonamide 4. Finally, cyclization of 
ET-1 was achieved by treating sulfonamide 4 with hydrochloric acid in dioxane. ET-2 
was obtained by treating ET-1 with iodomethane in dimethyl formamide. Stock solutions 
of the test compounds (50 mM) were prepared in DMSO. ET-1 and ET-2 both were more 
soluble than ellipticine. 
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Figure 26. Structures and synthetic pathway of the compounds ET-1 and ET-2. Top) 
The structures of ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole), N-methyl-5-
demethyl ellipticine (ET-1), and 2-methyl-N-methyl-5-demethyl ellipticinium iodide 
(ET-2) are shown.  Bottom) The approach used to synthesize ellipticine derivatives ET-1 
and ET-2 is shown. Reagents and Conditions: i) aminoacetaldehyde diethyl acetal, 
100 °C, stirred, 4 h.; ii) NaBH4, methanol, RT, stirred, 2 h.; iii) N(C2H5)3, chloroform, 
benzenesulfonyl chloride, stirred, RT, 18 h.; iv) 6 N HCl, dioxane, N2, reflux, 2 h.; v) 
CH3I, DMF, stirred, RT, 5 h. (Compounds synthesized by  collaborator Y. Ergun) 
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Effects of ET-1 and ET-2 on DNA Cleavage Mediated by Topoisomerase IIα  
 A number of assays were utilized to compare the effects of ET-1 and ET-2 on human 
topoisomerase IIα with those of the parent compound, ellipticine. First, the effects of the 
compounds on the overall catalytic activity of the enzyme were monitored using a 
decatenation assay (Figure 27). Both ET-1 and ET-2 inhibited the ability of 
topoisomerase IIα to unlink kinetoplast DNA (kDNA) rings and blocked enzyme activity 
completely at concentrations of 200-1000 µM. In contrast, ellipticine required a 
concentration of >5000 µM to completely inhibit the decatenation activity of the human 
type II enzyme. 
  Although topoisomerase II poisons act by enhancing levels of DNA cleavage, 
they still have the capacity to inhibit overall enzyme activity.
47,48
 Therefore, to determine 
whether ET-1 and ET-2 act specifically as catalytic inhibitors or also have the capacity to 
act as topoisomerase II poisons, their effects on topoisomerase IIα-mediated DNA 
cleavage was assessed (Figure 28). As reported previously, ellipticine was a modest 
inhibitor of DNA cleavage (IC50 >200 µM).
100,240
 Neither ET-1 nor ET-2 enhanced 
topoisomerase IIα-mediated DNA cleavage and both inhibited the DNA scission activity 
of the enzyme to a much greater extent than ellipticine. The IC50 for the two compounds 
were ~40 and 5 µM, respectively. 
 
Effects of ET-1 and ET-2 on Enzyme-DNA Binding 
  Catalytic inhibitors can block enzyme activity at a number of different steps of the 
topoisomerase II catalytic cycle.
47,96
 
56,67,97
 Compounds that inhibit the enzyme have been 
shown to act by blocking DNA binding, cleavage, or strand passage, or by interfering   
84 
 
 
 
 
 
Figure 27. Effects of ellipticine, ET-1, and ET-2 (8-5000 µM) on DNA decatenation 
catalyzed by human topoisomerase IIα. Assays containing intact kDNA in the absence 
of topoisomerase IIα (DNA), or kDNA treated with topoisomerase IIα in the absence of 
ellipticine-based compounds (TIIα) or in the presence of compound diluent (TIIα + 
DMSO) are shown as controls. The positions of intact kDNA at the origin (kDNA), 
decatenated nicked kDNA minicircles, and decatenated supercoiled kDNA minicircles 
are indicated. Gels are representative of three independent experiments. (Decatenation 
assay were performed by collaborators Z. Topcu and S. Zencir) 
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Figure 28. Effects of ellipticine, ET-1, and ET-2 on DNA cleavage mediated by 
human topoisomerase IIα. Results for ellipticine (ET; black), ET-1 (ET-1; red), and ET-
2 (ET-2; blue) on the generation of enzyme-mediated double-stranded DNA breaks are 
shown. DNA cleavage levels were calculated relative to control reactions that contained 
no drug and were set to 100%. Error bars represent standard deviations for at least three 
independent experiments. 
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with ATP binding/ hydrolysis. Because ET-1 and ET-2 inhibited DNA cleavage, we 
examined the effects of these compounds on topoisomerase IIα-DNA binding to 
determine whether the compounds are specific for DNA cleavage or act at a prior step in 
the catalytic cycle. ET-1 and ET-2 were used at 25 µM for this experiment, because DNA 
cleavage was inhibited substantially (~40 and 80% inhibition, respectively) at this 
concentration. Enzyme-DNA binding was monitored using an electrophoretic mobility 
shift assay (Figure 29). Neither ET-1 nor ET-2 displayed any ability to inhibit 
topoisomerase IIα-DNA binding at the concentration employed. In fact, ET-2 appeared to 
enhance enzyme-DNA binding by ~50%. Thus, we conclude that ET-1 and ET-2 act 
directly to inhibit DNA cleavage without altering the ability of topoisomerase IIαto bind 
its DNA substrate. 
 
Effects of ET-1 and ET-2 on DNA Intercalation 
 The ability of ellipticine to intercalate into DNA appears to play an important role 
in its antineoplastic activity.
248
 Because ET-1 and ET-2 are more potent inhibitors of 
human topoisomerase IIαthan ellipticine, a topoisomerase I-DNA unwinding assay was 
utilized to compare the ability of these compounds to intercalate into relaxed plasmid 
DNA (Figure 30). As determined by the shift in the plasmid from relaxed to negatively 
supercoiled DNA, all of the compounds intercalated into DNA. Similar to the inhibition 
of DNA cleavage observed with the compounds (see Fig. 28), the relative potency of 
intercalation was ET-2>ET-1>>ellipticine. This finding suggests that the ability of the 
ellipticine derivatives to inhibit the activity of topoisomerase IIαis related to their ability 
to intercalate into the double helix.  
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Figure 29. Effects of  ET-1 and ET-2 on the binding of negatively supercoiled 
plasmid by human topoisomerase IIα. Results of an electrophoretic mobility shift assay 
are shown for an enzyme titration carried out in the presence of no compound, 25 µM 
ET-1, or 25 µM ET-2. Enzyme-DNA binding is indicated by the shift of the DNA from 
the position of negatively supercoiled [(-)SC] plasmid to the origin. Gels are 
representative of three independent experiments. 
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Figure 30. Intercalation of ellipticine (ET), ET-1, and ET-2 into relaxed DNA. 
Results of a topoisomerase I-DNA unwinding assay are shown. Intercalation is indicated 
by the shift in the position of the plasmid from relaxed (Rel) to negatively supercoiled [(-
)SC] DNA. A strong intercalator, ethidium bromide (10 µM), and a non-intercalator, 
etoposide (250 µM), are shown as positive and negative controls, respectively. Assays 
that contained only the relaxed DNA substrate (DNA) or relaxed DNA and 
topoisomerase I with no compound (NC) are shown. Gels are representative of three 
independent experiments. 
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 Conclusions 
 
 There is a need for the development of new anticancer drugs. Given the 
demonstrated antineoplastic activity of ellipticine, derivatives of this compound have the 
potential to display greater activity against cells or enzyme targets.
244,252,253
 Results of the 
present study indicate that ET-1 and ET-2 are catalytic inhibitors of human 
topoisomerase IIα. Furthermore, both are more potent than ellipticine, and the activity of 
ET-1 and ET-2 toward the type II enzyme appears to be related to their enhanced ability 
to intercalate into DNA. 
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CHAPTER V 
 
EFFECTS OF SECONDARY METABOLITES FROM THE FUNGUS 
SEPTOFUSIDIUM BEROLINENSE ON DNA CLEAVAGE MEDIATED BY HUMAN 
TOPOISOMERASE IIα 
 
Introduction 
 
 Fungi are a rich source of bioactive metabolites and many of them display 
antineoplastic activity in cancer models.
135,254-256
 Recently, two compounds that are 
cytotoxic to a variety of human cancer cell lines were isolated from the filamentous soil 
fungus, Septofusidium berolinense.
203
 Based on mass spectroscopy and 
13
C and 
1
H NMR 
analysis, one of these metabolites was identified as 3,6-dihydroxy-2-propylbenzaldehyde 
(GE-1),
203
 which is a hydroquinone, and the other was identified as 2-hydroxymethyl-3-
propylcyclohexa-2,5-diene-1,4-dione (GE-2),
203,257
 which is a quinone (Figure 31). At the 
present time, nothing is known about the targets that mediate the cytotoxicity of GE-1 
and GE-2. 
 Several naturally occurring polyphenols act as topoisomerase II poisons.
57,84
 
These include quinones (benzoquinone, curcumin oxidation products, and thymoquinone), 
58,103,108,112
 hydroquinone,
108,110
 and catechols (quercetin, epigallocatechin gallate, 
hydroxytyrosol, and oleuropein).
147,154,194
 Some of these compounds work by a unique 
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Figure 31. Structures of two secondary metabolites isolated from the fungus 
Septofusidium berolinense. 3,6-dihydroxy-2-propylbenzaldehyde (GE-1) is a 
hydroquinone and 2-hydroxymethyl-3-propylcyclohexa-2,5-diene-1,4-dione (GE-2) is a 
quinone. 
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 mechanism and are believed to enhance topoisomerase II-mediated DNA cleavage by 
forming covalent adducts with the enzyme. Consequently, they are referred to as covalent 
topoisomerase II poisons.
19,57
 
 Because GE-1 and GE-2 have structural elements consistent with some 
established topoisomerase II poisons, the effects of these fungal metabolites on the DNA 
cleavage activity of human topoisomerase IIα were assessed. Results strongly suggest 
that GE-2 is a covalent topoisomerase II poison. Although GE-1 does not enhance 
enzyme-mediated DNA scission under normal assay conditions, the presence of an 
oxidant converts the metabolite into an efficacious topoisomerase II poison. These 
findings suggest that topoisomerase IIα may be a cytotoxic target for GE-2 and 
potentially GE-1 in human cells. 
 
Results and Discussion 
 
Effects of GE-1 and GE-2 on DNA Cleavage Mediated by Topoisomerase IIα 
 Humans encode two isoforms of topoisomerase II, α and .13,18,25,27,68 
Topoisomerase IIα is the isoform that is highly expressed in rapidly proliferating cells 
and is responsible for unlinking daughter chromosomes. The enzyme is also an important 
target for anticancer drugs.
13,18,19,27,56,68
 Therefore, topoisomerase IIα was used to analyze 
the effects of GE-1 and GE-2 on enzyme-mediated DNA cleavage. 
 GE-2, which is a quinone, enhanced DNA cleavage mediated by topoisomerase 
IIα ~4–fold (Figure 32). In contrast, GE-1, which is a hydroquinone, displayed no ability 
to increase DNA cleavage at concentrations as high as 1 mM. Moreover, over this  
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Figure 32. The effects of GE-1 and GE-2 on DNA cleavage mediated by human 
topoisomerase IIα. Double-stranded DNA cleavage levels in the presence of 0-1000 µM 
GE-1 (red) or GE-2 (blue) were calculated relative to a reaction that contained enzyme 
but no compound. A DNA control also is shown (DNA). Error bars represent standard 
deviations for at least three independent experiments. Ethidium bromide-stained agarose 
gels depicting DNA cleavage are shown (top). The mobility of negatively supercoiled 
DNA (form I; FI), nicked circular plasmid (form II; FII), and linear molecules (form III; 
FIII) are indicated. Gels are representative of five independent experiments. 
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concentration range, GE-1 inhibited DNA scission by ~40%. Previous studies found that 
1,4-hydroquinone could act as a topoisomerase II poison, but required concentrations that 
were 5-10–fold higher than that of the corresponding 1,4-benzoquinone.103,110 Therefore, 
the effects of 5 mM GE-1 on topoisomerase IIα-mediated DNA cleavage were assessed. 
At this concentration, GE-1 increased levels of DNA scission ~2.8–fold (data not shown). 
This activity of GE-1 seen at high concentrations may reflect low levels of redox cycling 
that converts the metabolite from a hydroquinone to a quinone under assay conditions. 
 The effects of GE-1 and GE-2 (0-1 mM) on DNA cleavage site utilization by 
topoisomerase IIα are shown in Figure 33. GE-2 increased scission at several sites and 
produced a banding pattern similar to that of etoposide. Consistent with the results seen 
with plasmid DNA, GE-1 decreased enzyme-mediated scission at all observable sites. 
 In order to ensure that DNA cleavage induced by GE-2 was mediated by 
topoisomerase IIα, three control reactions were performed in the presence of 250 µM 
metabolite (Figure 34). First, no DNA scission was observed when GE-2 was incubated 
with DNA in the absence of the type II enzyme. Second, DNA cleavage was reversed 
when the active site Mg
2+
 ions were chelated with EDTA prior to trapping cleavage 
complexes with SDS. This reversibility is not consistent with an enzyme-independent 
reaction. Third, cleaved plasmid products were covalently linked to topoisomerase IIα. 
When proteinase K treatment was omitted, the free linear DNA band disappeared and 
was replaced by a lower mobility smear that extended to the origin.  
 Finally, consistent with previous results with the quinone-based topoisomerase II 
poison thymoquinone,
112
 GE-2 induced stable cleavage complexes with the α isoform 
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Figure 33. Effects of GE-1 and GE-2 on DNA cleavage site utilization by human 
topoisomerase IIα. An autoradiogram of a 6% polyacrylamide gel is shown. A singly 
32
P-end-labeled linear 4332 bp fragment of pBR322 was used as the cleavage substrate. 
DNA cleavage reactions were carried out in the presence of 0-1000 µM GE-1 or GE-2, or 
10 µM etoposide (as a positive control, Etop). A DNA control also is shown (DNA). 
Results are representative of three independent experiments. 
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Figure 34. DNA cleavage induced by GE-2 is reversible and protein-linked. Assay 
mixtures contained DNA and 250 µM GE-2 in the absence of enzyme (-TII), DNA in the 
presence of topoisomerase IIα in the absence of GE-2 (+TII), or reaction mixtures that 
contained DNA, enzyme, and 250 µM GE-2 that were stopped with SDS (SDS). To 
determine whether the reaction was reversible, EDTA was added prior to SDS (EDTA). 
To determine whether the cleaved DNA was protein-linked, proteinase K treatment was 
omitted (ProK). The mobility of negatively supercoiled DNA (form I; FI), nicked circular 
plasmid (form II; FII), and linear molecules (form III; FIII) are indicated. Error bars 
represent the standard deviation of three independent experiments. A gel that is 
representative of three independent experiments is shown (top). 
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 (not shown). The t1/2 of DNA cleavage mediated in the presence of GE-2 was ≥ 24 h 
(levels of cleavage complex remaining = 58 ± 18%). 
 
GE-2 Is a Covalent Topoisomerase II Poison 
 First, to assess the requirement for the N-terminal domain, the effects of 250 µM 
GE-1 and GE-2 on DNA cleavage mediated by the catalytic core of topoisomerase IIα 
were determined (Figure 35). Whereas etoposide enhanced DNA cleavage, no cleavage 
increase was observed in the presence of GE-1 or GE-2. In addition, neither fungal 
metabolite was able to diminish the effects of etoposide on DNA cleavage mediated by 
the catalytic core, suggesting that they were unable to compete with the interfacial poison 
at the active site of topoisomerase IIα (not shown). 
 Second, 250 µM GE-2 was incubated with topoisomerase IIα prior to the addition 
of DNA (Figure 36). Consistent with the actions of covalent poisons, the metabolite 
rapidly inactivated enzyme-mediated DNA cleavage (t1/2 ≈ 1.5 min). In contrast, 
incubation with the interfacial poison etoposide (200 µM) had no effect on DNA 
cleavage at 3 min (Figure 36). 
 Third, the addition of DTT to GE-2 completely blocked its ability to enhance 
DNA cleavage mediated by topoisomerase IIα (Figure 37). In contrast, incubation of 
etoposide with DTT or other reducing agents has no significant effect on its activity 
against the human enzyme.
147
 
 Finally, the addition of oxidants to some catechols greatly enhances their potency 
as topoisomerase II poisons.
194
 Presumably, oxidation converts the catechols to more 
reactive quinone-based species,
258
 which can more readily adduct the type II enzyme. 
98 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35.  GE-1 and GE-2 require the N-terminal domain in order to enhance DNA 
cleavage mediated by topoisomerase IIα. The effects of GE-1 and GE-2 on DNA 
cleavage mediated by the catalytic core of human topoisomerase IIα (which lacks both 
the C-terminal and N-terminal domains) are shown. DNA cleavage reactions were carried 
out using 250 µM metabolite or 100 µM etoposide. A DNA control (DNA) and a 
cleavage reaction carried out in the absence of compounds (TII) also are shown. An 
EcoRI-digested plasmid control (EcoRI) is shown to depict the position of linear DNA 
and represents 100% double-stranded DNA cleavage. The gel is representative of three 
independent experiments. 
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Figure 36. GE-2 inactivates human topoisomerase IIα when incubated with the 
enzyme prior to the addition of DNA. Cleavage reactions were initiated after 
topoisomerase IIα was incubated with 250 µM GE-2 for 0-3 min (blue). Double-stranded 
DNA cleavage levels were calculated relative to scission induced when GE-2 and the 
enzyme were not incubated prior to initiation of the DNA cleavage assay. Results for a 
control reaction in which topoisomerase II was incubated with 200 µM etoposide for 3 
min (Etop, open black) are shown. Error bars represent standard deviations for at least 
three independent experiments. 
100 
 
 
 
Figure 37. Effects of reducing and oxidizing reagents on the activities of GE-1 and 
GE-2 in topoisomerase IIα-mediated DNA cleavage reactions. DNA cleavage 
reactions were carried out in the absence of a reducing/oxidizing reagent (-Redox; solid 
bars), or in the presence of 50 µM K3Fe(CN)6 (+ oxidant; open bars) or 250 µM reducing 
agent (+DTT; stippled bars). Results are shown in the absence of compound [(NC); gray], 
or in the presence of 250 µM GE-1 (red) or GE-2 (blue). In reactions that contained the 
reducing or oxidizing reagent, metabolites were incubated with these reagents for 10 min 
prior to the start of the 6-min cleavage reaction. DNA cleavage levels were calculated 
relative to that of a control reaction that contained no metabolites or reducing/oxidizing 
reagents. Error bars represent standard deviations for at least three independent 
experiments. 
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 Oxidation had no effect on the activity of GE-2, which already was a quinone (Figure 
37). In marked contrast, the presence of an oxidant [K3Fe(CN)6] dramatically increased 
the activity of GE-1. Whereas GE-1 displayed no ability to enhance topoisomerase IIα-
mediated cleavage at 1 mM (see Figure 32), oxidized GE-1 enhanced DNA scission ~5–
fold at 250 µM (Figure 37).  
 
Conclusions 
 
 Fungal metabolites are a rich source of compounds with biological activity.
135,254-
256
 Recently, two compounds with antineoplastic activity were isolated from the 
filamentous soil fungus, S. berolinense. GE-2, a quinone-based compound, enhanced 
DNA cleavage mediated by topoisomerase IIα in a concentration range at which it was 
reported to be cytotoxic to human cancer cell lines.
203
 Furthermore, the compound 
displayed all of the hallmarks of a covalent topoisomerase II poison. GE-1, a 
hydroquinone-based compound, displayed little activity toward the human enzyme except 
at high concentrations. However, its activity and potency improved considerably under 
oxidizing conditions. Results of the present study suggest that topoisomerase IIα may 
play a role in mediating at least some of the antineoplastic effects of these fungal 
metabolites. 
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CHAPTER VI 
  
CONCLUSIONS AND FUTURE DIRECTIONS  
 
Nature is an attractive source for new therapeutic candidate compounds, due to 
the chemical scaffold diversity found in millions of species of plants, animals, marine 
organisms and microorganisms. In this regard, plant-based drugs have molded the basis 
of traditional medicine for millennia. Over the years natural products have become the 
single most productive source of leads for the development of drugs.
139,140
 Notably, 
nearly half of the anticancer drugs approved internationally have been developed from 
either natural products or their derivatives.
135,140,141
  
Natural therapies, such as the use of the plants or plant derived natural products 
have proven beneficial to combat cancer, even though some of the specific cellular 
targets are ill-defined. With an estimated 80-85% of the global population still relying on 
traditional medicines for their primary healthcare needs and the number of side effects 
associated with the use of synthetic drugs, it is worthwhile to understand current 
medicinal herbs and further identify potential natural products that have effects on 
specific cellular targets and characterize their mechanism of action.
138
    
Along with traditional and modern medicine, natural dietary agents including 
fruits, vegetables, and spices have demonstrated the ability to suppress cancers.
93,141,146
 
Recent studies suggest that the consumption of food rich in fruits, vegetables and spices 
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have a lower incidence of cancers (stomach, esophagus, lung, oral cavity and pharynx, 
endometrium, pancreas and colon). Although the advancement of research has led to 
some progressive alternative treatments, a vast amount of information remains to be 
exposed, verified, and applied. 
The research described in this dissertation was carried out to help uncover natural 
metabolites that target human topoisomerase IIα and further characterize the mechanism 
of topoisomerase II covalent poisons.  Further identification and characterization of new 
topoisomerase II poisons may provide a platform for developing new anticancer and 
chemopreventative therapies. 
 
Olive Metabolites as Topoisomerase II-Targeting Anticancer Agents 
 
  The Mediterranean basin is home to a biologically diverse plant biome and is a 
particularly rich source of botanicals with medicinal properties.
93,216,217
 Phytochemicals 
derived from Mediterranean plant species have been shown to provide a variety of health 
benefits and display anti-inflammatory, anticancer, cardioprotective, and 
chemopreventative properties.
93,216,217
  
  Therefore, in an effort to discover novel phytochemicals with activity against 
human type II topoisomerases, research was carried out on a blind screen of a library of 
341 Mediterranean plant extracts to determine whether any of them increased levels of 
DNA cleavage mediated by topoisomerase IIα. As described in chapter III, an extract 
from Phillyrea latifolia L., a member of the Oleaceae family of olive trees, displayed 
high activity against the human enzyme. A search of previously published metabolomics 
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studies on the specific plant specimen identified several polyphenols that could be 
potential candidates for topoisomerase II poisons. Hydroxytyrosol, oleuropein, and 
verbascoside were determined to act as covalent topoisomerase II poisons. Additionally, 
the activities of these compounds against the enzyme were accentuated under oxidizing 
conditions. Furthermore, water-soluble extracts of an herbal supplement from olive leaf 
extracts, as well as extra virgin olive oils pressed from a variety of O. europea 
subspecies, also enhanced DNA cleavage mediated by human topoisomerase IIα. Thus, 
olive metabolites appear to act as topoisomerase II poisons even in complex formulations 
intended for human dietary consumption. Results of the present study suggest that the 
ability of these olive metabolites to poison topoisomerase II may contribute to their 
therapeutic properties.  
  The covalent topoisomerase II poisons, hydroxytyrosol, oleuropein, and 
verbascoside, are well-established antioxidants and are believed to have 
chemopreventative properties.
226,259,260
 In particular, hydroxytyrosol is the most powerful 
antioxidant known and is currently in clinical trials as a chemopreventative agent for 
women at high risk for breast cancer.
232
 Researchers have found that hydroxytyrosol, 
oleuropein, and verbascoside induce cell cycle arrest, display anti-proliferative effects, 
and show activity against in vivo tumor models.
226-231
 Furthermore, these compounds are 
naturally present in olives and olive oil, key components of the Mediterranean diet, and 
epidemiological observations have indicated that this diet has great potential for cancer 
prevention.
93,223,234,235
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Ellipticine Derivatives as Topoisomerase II-Targeting Anticancer Agents 
 
  The main reason for clinical interest in ellipticine and its derivatives is their 
effectiveness against several types of cancer, and their complete lack of hematological 
toxicity.
238,243,244,246
 These DNA damaging compounds affect cells through multiple 
mechanisms, including cell cycle arrest and the initiation of apoptosis.
243,244
 Ellipticine, a 
natural product first isolated from the Australian evergreen tree, is a well-known 
antineoplastic agent whose proposed mode of action is based mainly on DNA 
intercalation and targeting human topoisomerase II. In contrast to the parent compound, 
several ellipticine derivatives are potent topoisomerase II poisons in mammalian systems 
and display anticancer activity against human breast cancer and other solid 
tumors.
238,244,245
 Unfortunately, these compounds induce a number of adverse effects such 
as dry mouth, weight loss, hemolysis, and renal toxicity. Given the demonstrated 
antineoplastic activity of ellipticine, derivatives of this compound have the potential to 
display greater activity against cells or enzyme targets.
244,252,253
  
  In an attempt to develop ellipticine analogs with greater anticancer activity, 
increased solubility, and less secondary effects, two novel C5-demethylated analogs were 
synthesized by our collaborators. To assess the effects of the new ellipticine-based 
compounds for their potential as topoisomerase II-targeted drugs, ET-1 and ET-2 were 
tested against human topoisomerase II activity. Results from these studies, described in 
chapter IV, indicate that ET-1 and ET-2 are catalytic inhibitors of human topoisomerase 
IIα. Furthermore, both demethylated analogs are more potent than ellipticine and the 
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activity of ET-1 and ET-2 toward the type II enzyme appears to be related to their 
enhanced ability to intercalate into DNA.  
  Although ET-1 and ET-2 are topoisomerase IIα inhibitors, they do not inhibit the 
ability of the enzyme to bind the DNA and actually appear to enhance DNA binding. 
Thus, these two catalytic inhibitors must be acting on another step within the 
topoisomerase II catalytic cycle, presumably at the DNA cleavage step.  
  It is clear that additional biochemical studies are needed to fully understand the 
role of ET-1 and ET-2. These studies might include the investigation of the effects of ET-
1 and ET-2: on DNA alteration, on topoisomerase II ATPase activity, on topoisomerase 
II binding parameters, on cleavage site-specificity, on topoisomerase II clamp-closing 
activity, and on isoform specificity. Further research, such as that listed, might help to 
identify the specific catalytic step that is responsible for the inhibition of topoisomerase II 
activity and additional functions of the compounds. 
 
Fungal Metabolites as Topoisomerase II-Targeting Anticancer Agents 
 
  Bioactive natural products can be produced by almost all types of living 
organisms, even soil bacteria and fungi. Soil fungi, in particular are a rich source of 
compounds with biological activity. These organisms have unique biochemical pathways 
that produce a wide range of natural products such as penicillin, cyclosporin, statins, 
aflatoxins, trichothecenes and ergot alkaloids.
261,262
 Research has shown that filamentous 
fungi are frequent producers of secondary metabolites, yet only a small portion of these 
have been cultivated and screened for new bioactive compounds. Due to the increasing 
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demand for new bioactive natural products, the use of fungal diversity in the search for 
new bioactive molecules has become of significant interest.
254,255 263 
  In a search for bioactive molecules from filamentous fungi, two compounds with 
antineoplastic activity were isolated from the filamentous soil fungus, S. berolinense. As 
described in chapter V, GE-2, a quinone-based compound, enhanced DNA cleavage 
mediated by topoisomerase II in a concentration range at which it is cytotoxic to human 
cancer cell lines.
203
 Furthermore, the compound displayed all of the hallmarks of a 
covalent topoisomerase II poison. GE-1, a hydroquinone-based compound, displayed 
little activity toward the human enzyme except at high concentrations. However, its 
activity and potency improved considerably, under oxidizing conditions. The results 
presented in this study suggest that topoisomerase II may play a role in mediating, at 
least in part, the antineoplastic effects of these two fungal metabolites.  
  A number of fungal metabolites have been identified as healthcare agents 
(antibiotics, immunosuppressants, hypocholesterolemics, and antifungals). However, soil 
fungi have been scarcely explored and could contain potential novel anticancer molecules. 
Further systematic screening (phytochemical, biochemical, and bioinformatics 
approaches) of filamentous soil fungi species for novel metabolites and identification of 
their cellular targets and effects may help to identify new anticancer agents from soil 
fungi.  
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APPENDIX 
 
POSSIBLE COVALENT ADDUCTION SITES ON HUMAN TOPOISOMERASE IIα 
 
Introduction 
 
Many quinone-based metabolites (1,4-benzoquinone, N-acetyl-p-benzoquinone 
imine (NAPQI), polychlorinated biphenyl quinones (PCB), oxidized curcumin 
metabolites, and (Thymoquinone) and isothiocyanates have been found to enhance 
topoisomerase IIα-mediated DNA cleavage through a covalent poison mechanism.58,84,102-
105,112,114,264
 Quinone-based compounds can naturally be produced in the body as a result 
of metabolism either by reactive oxygen species or modifying enzyme. These compounds 
can also be a product of the species’ metabolism from which it came from. Quinone-
based and isothiocyanates compounds are highly reactive and have been found to act on 
topoisomerase II either by inhibiting the rate of religation or by blocking the N-terminal 
gate by crosslinking both subunits. These resulting mechanisms could be the effect of 
adduction to a single site or multiple sites within the enzyme.
57,67
   
 Research has suggested that thiol modification is the mechanism of covalent 
topoisomerase poisons, and that the rate of thiol modification depends on both the 
chemical structure of the thiol-reactive compounds and the structural microenvironment 
in the vicinity of the -SH group.
84,104,105,107,265
 With there being 13 cysteine residues that 
are located throughout human topoisomerase IIα, a single or multiple of these could be 
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modified by covalent topoisomerase II poisons. Identification of the key cysteine residues 
on topoisomerase IIα that are responsible for thiol modification have been of interest to 
understand the covalent topoisomerase II poison mechanism.
104,105,107,265,266
 These studies 
may also help design novel topoisomerase IIα-selective drugs. 
Initial characterization studies by Hasinoff et. al. showed that topoisomerase IIα 
contained at least five free cysteines (170, 216, 300, 392, and 405), two disulfide-bonded 
cysteine pairs (427–455 and 997-1008), and a possible disulfide pair that included 
cysteine 733.
265
More recent research by Chen et. al. has further exposed and categorized 
the reactivities of cysteines within topoisomerase IIα  as the following 1) high reactivity 
(>10%), C104, C216, C427, and C1145;  2) medium reactivity (2∼10%), C170, C300, 
C392, and C405; and 3) low reactivity (<2%), C455, C733, C862, and Cys-997/Cys-1008 
(Figure 38).
266
   
The mechanism by which human topoisomerase IIα is targeted by quinone drugs 
is most characterized.
106,113,114,116,262
 Bender et al. investigated amino acids residues in 
human topoisomerase II α that are modified by quinones. Cysteine residues 170, 392 and 
405, located on the N-terminal domain, and 455 located in the catalytic core were able to 
be modified by a quinone-based compound as assessed by mass spectrometry. These 
findings indicated that adduction of C392 and C405 is important for the actions of 
quinones against the enzyme and increased levels of cleavage complexes primarily by 
inhibiting DNA religation.
104
 Interestingly, the C445A mutant that was proposed to 
partner with the accessible, yet mobile, C427 in a disulfide bond was hypersensitive to 
benzoquinone and other covalent poisons.
265,266
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Figure 38.  Reactivity of topoisomerase IIα cysteines. Previous research evaluated the 
cysteine accessibility within human topoisomerase IIα, using pulsed alkylation with mass 
spectrometric analysis. The 13 possible cysteines were categorized based on reactivity 
with the alkylating agent mBrB-d6: 1) high reactivity (>10%), 2) medium reactivity 
(2∼10%), and 3) low reactivity. Figure reproduced from Ref. 266. 
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Furthermore, research in my dissertation work indicated that C104 may be 
adducted by hydroxytyrosol, based on differences in mass spectroscopy analysis (Figure 
22). Based upon these data, the effects of cysteine to alanine mutations of residues 104, 
427, and 427/455 on topoisomerase IIα activity and susceptibility to covalent poisons 
were investigated. The location of most of these cysteines is indicated in Figure 39. 
 
Results and Discussion 
 
Stability of Mutant Enzymes 
The human topoisomerase IIα mutant enzymes, C427A and C427A/455A, 
displayed low stability through several purification techniques (affinity, affinity+p-cell, 
and ionic exchange+p-cell) (Figure 40). As discussed above, these two cysteine residues 
are suggested to pair in a disulfide bond, and C427 is a rather mobile reactive residue.
266
 
Thus, mutation of C427 to an alanine is the proposed cause of the enzyme instability and 
decreased levels of enzyme. Ultimately, this instability prevented the isolation of pure 
active enzyme. His-tagged wild-type, C104A and C455A human topoisomerase IIα were 
purified through the standard affinity+p-cell chromatography without degradation and 
displayed a baseline level of DNA cleavage (Figure 40).  
 
Activity of the C104A Mutant Enzyme 
Basal DNA relaxation and cleavage activity by the C104A mutant was decreased 
(~40%) compared to wild-type (Figures 40). Further investigation revealed that etoposide  
112 
 
 
 
Figure 39. Location of human topoisomerase IIα cysteine residues. A homology 
model of human topoisomerase IIα is shown. The location of each cysteine is highlighted 
in yellow, except cysteine residue 427.  Figure reproduced from Ref. 266. 
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Figure 40. Effects on protein stability and baseline cleavage activity of cysteine to 
alanine mutations of 104, 427, and 427/455. A) Samples of purified wild-type and 
mutant human topoisomerase IIα are represented in the separate gel images (7.5% 
polyacrylamide). Std. represents the untagged wild-type enzyme. His-tagged wild-type 
and C455A were used as purification controls B) Baseline DNA cleavage levels of His-
tagged C104A and WT enzymes were measured. Percent DNA cleavage was compared 
to a linear Eco RI control set to 100%.  C) Relaxation of supercoiled pBR322 by the His-
tagged C104A and WT was monitored at a range of enzyme dilutions (0-1:50). Untagged 
wild-type human topoisomerase IIα was used as a positive control and the enzyme at a 
1:5 dilution in the absence of ATP (No ATP) was used as a negative control. All assays 
are representative of three or more sets of experiments. 
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had an effect on DNA cleavage mediated by the C104A mutant enzyme that was similar 
to its effects on wild-type topoisomerase IIα. (Figure 41) In contrast, the C104A mutant 
was hypersensitive to the covalent poison hydroxytyrosol and displayed an increased 
potency toward the compound as compared to the wild-type enzyme. Similarly, 
hydroxytyrosol induced greater levels of DNA cleavage with the C104A mutant in the 
presence of 10 µM oxidant than it did with the wild-type enzyme (Figure 41).  
 
Conclusions 
If we assume mutation of C104 mimics covalent adduction to this residue, two 
mechanisms can be proposed. 1) Modification of this residue decreases enzyme activity, 
but not to an extent where the residue is crucial for activity; therefore, other reactive 
residues must be involved. 2) Although the activity is decreased in the absence of drug, 
modification of this residue alters the enzyme so that it can position other reactive 
residues to be more accessible, leading to enzyme hypersensitivity and increased potency 
towards the covalent compound. In either case, C104A is not proposed to be a lone 
residue affected by adduction, simply a modifier of the enzyme that leads to changes in 
enzyme activity. However, the mechanism of action could be even more complicated 
than originally believed, with a mixture of reactive residues having various 
inhibition/activation activities.  
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Figure 41. Effects of an interfacial and covalent poison on DNA cleavage activities 
mediated by His-tagged wild-type and C104A mutant human topoisomerase IIα. 
His-tagged C104A and WT-mediated DNA cleavage of etoposide (0-200 µM) (left), 
hydroxytyrosol (0-1000 µM) (middle), and 100 µM hydroxytyrosol in the presence 10 
µM oxidant (right) was assessed. Relative cleavage was compared to a no drug control. 
All assays are representative of three or more sets of experiments. 
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MATERIALS AND METHODS PREPARED BY COLLOABORATORS 
 
Materials and methods 
 
Plant extract preparation  
A library of methanol/water extracts from 341 native Mediterranean plants was 
used for the initial screening. Plant species were mainly from arid lands or the Tel Aviv 
University Botanical Garden and included plants used in traditional Bedouin 
medicine.
204-206
 Based on results with the original library, a second library of 36 extracts 
from the leaf, bark, flowers, or fruit of 11 individual olive tree species was established.  
 Plant extracts were prepared as described by Kaiser et al.
207
 Briefly, samples (1 g) 
of frozen plant material were ground in a pre-chilled mortar containing liquid nitrogen. 
Two mL of methanol/water (50/50, v/v) were added, and slurries were mixed and kept on 
ice for 15 min. The mixtures were centrifuged at 11,000 rpm for 5 min at room 
temperature using a Hermle Z160M microfuge. Supernatant liquids were stored at -80 °C 
for analysis. Extract concentrations were determined gravimetrically. Samples were dried 
in vacuo, de-identified, numbered, and stored at -20 °C. 
 
Chemistry 
N-((4,9-Dimethyl-9H-carbazol-3-yl)methylene)-2,2-diethoxyethanamine (2) 
  A mixture of carbazole aldehyde 1 (2 g, 9 mmoles) and aminoacetaldehyde 
diethyl acetal (1 g, 9 mmoles) was heated at 100 °C under nitrogen for 4 h. Benzene (50 
mL) was added to the reaction mixture and evaporated twice in order to remove water 
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and volatile components. The crude product was crystallized from hexane-benzene to 
yield imine 2. Yield: 3 g, 100%; mp: 95 °C; IR (KBr) νmax: 2972 (CH), 1624 (C=N), 1112 
(C-O-C) cm
-1
; 
1
H-NMR (CDCl3, 400 MHz): δ 1.09 (t, 6H, J= 7.2 Hz, 2xCH3), 2.94 (s, 3H, 
CH3), 3.52 (q, 4H, J= 7.6 Hz, OCH2), 3.64 (q, 4H, J= 7.6 Hz, OCH2), 3.71 (d, 2H, J= 5.6 
Hz, CH2), 3.83 (s, 3H, NCH3), 4.74 (t, 1H, J= 5.2 Hz, CH), 7.22 (t, 1H, J= 7.6 Hz, ArH), 
7.41-7.48 (m, 2H, ArH), 7.58 (d, 1H, J= 8.4 Hz, ArH), 7.98 (d, 1H, J= 9.2 Hz, ArH), 8.20 
(d, 1H, J= 8.4 Hz, ArH), 8.79 (s, 1H, =CH); Anal. Calcd for C21H26N2O2; C, 74.52; H, 
7.74; N, 8.28. Found: C, 74.43; H, 7.67; N, 8.25. 
N-((4,9-Dimethyl-9H-carbazol-3-yl)methyl)-2,2-diethoxyethanamine (3) 
  A solution of imine 2 (2 g, 6 mmoles) in methanol (50 mL) was cooled to 0 °C 
and sodium borohydride (2.3 g, 60 mmoles) was added in portions. The reaction mixture 
was stirred at room temperature for 2 h. The methanol was removed in vacuo, water was 
added, and the mixture was extracted with chloroform. The organic phase was dried with 
anhydrous magnesium sulfate and the solvent was removed in vacuo. The residue was 
recrystallized from ether to yield amine 3. Yield: 1.85 g, 92%; mp: 117°C; IR (KBr) νmax: 
3220 (NH), 2935 (CH), 1150 (C-O-C) cm
-1
; 
1
H-NMR (CDCl3, 400 MHz): δ 1.11 (t, 6H, 
J= 7.2 Hz, 2xCH3), 2.16 (bs, 1H), 2.96 (s, 3H, CH3), 3.51 (q, 2H, J= 7.6 Hz, OCH2), 3.60 
(q, 2H, J= 7.6 Hz, OCH2), 3.72 (d, 2H, J= 5.6 Hz, CH2), 3.83 (s, 3H, NCH3), 4.35 (s, 2H, 
ArCH2), 4.74 (t, 1H, J= 5.2 Hz, CH), 7.22 (t, 1H, J= 7.6 Hz, ArH), 7.41-7.48 (m, 2H, 
ArH), 7.58 (d, 1H, J= 8.4 Hz, ArH), 7.98 (d, 1H, J= 9.2 Hz, ArH), 8.20 (d, 1H, J= 8.4 Hz, 
ArH); Anal. Calcd for C21H28N2O2; C, 74.08; H, 8.29; N, 8.23. Found: C, 73.93; H, 8.24; 
N, 8.19. 
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N-(2,2-Diethoxyethyl)-N-((4,9-dimethyl-9H-carbazol-3-yl)methyl)benzenesulfonamide(4) 
  A solution of amine 3 (2 g, 6 mmoles) and triethyl amine (1.2 g, 12 mmoles) in 
chloroform (20 mL) was cooled to 0 °C. Benzenesulphonyl chloride (1.14 g, 6.5 mmoles) 
in chloroform (10 mL) was added drop-wise and the solution was stirred for 18 h at room 
temperature. The reaction mixture was diluted with chloroform and washed with 
hydrochloric acid (100 mL, 10%). The organic layer was dried over anhydrous 
magnesium sulfate and the solvent was removed in vacuo and the resulting residue was 
isolated. The crude product was purified using silica gel and ethyl acetate-hexane (1:1). 
The solvent was removed in vacuo and the crude product was recrystallized from 
methanol to yield sulfonamide 4. Yield: 2.4 g, 85%; mp: 105 °C; IR (KBr) νmax: 2927 
(CH), 1330 (SO), 1171 (C-O-C) cm
-1
; 
1
H-NMR (CDCl3, 400 MHz): δ 1.04 (t, 6H, J= 7.2 
Hz, 2xCH3), 2.84 (s, 3H, CH3), 3.19 (d, 2H, J= 5.6 Hz, CH2), 3.25 (q, 2H, J= 7.6 Hz, 
OCH2), 3.47 (q, 2H, J= 7.6 Hz, OCH2), 3.79 (s, 3H, NCH3), 4.38 (t, 1H, J= 5.6 Hz, CH), 
4.70 (s, 2H, ArCH2), 7.15 (d, 1H, J= 8.8 Hz, ArH), 7.23 (t, 1H, J= 8 Hz, ArH), 7.31 (d, 
1H, J= 8 Hz, ArH), 7.39 (d, 1H, J= 8 Hz, ArH), 7.42-7.52 (m, 3H, ArH), 7.54 (d, 1H, J= 
7.2 Hz, ArH), 7.87 (d, 2H, J= 7.2 Hz, ArH), 8.22 (d, 1H, J= 8.4 Hz, ArH); Anal. Calcd 
for C27H32N2SO4; C, 67.47; H, 6.71; N, 5.83; S, 6.67. Found: C, 67.32; H, 6.75; N, 5.81; 
S, 6.65. 
N-Methyl 5-demethyl-ellipticine (ET-1) 
  Sulfonamide 4 (2 mmoles) was resuspended in dioxane (20 ml). Hydrochloric 
acid (2.5 mL, 6 N) was added, and the mixture was refluxed under nitrogen for 2 h. The 
reaction mixture was dissolved in water and extracted with chloroform. After the 
evaporation of solvent, the residue was chromatographed using silica gel and methanol. 
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The solvent was evaporated and the residue was recrystallized from ether to yield 
ellipticine derivative ET-1 as a yellow powder. Yield: 400 mg, 80%; mp: 297°C; IR 
(KBr) νmax: 3042 (CH), 2913 (CH), 1626 (C=N) cm
-1
; 
1
H-NMR (CDCl3, 400 MHz): δ 
2.99 (s, 3H, CH3), 3.68 (s, 3H, NCH3), 7.26 (t, 1H, J= 7.6 Hz, ArH), 7.45 (d, 1H, J= 8.4 
Hz, ArH), 7.54 (t, 1H, J= 7.6 Hz, ArH), 7.78 (s, 1H, ArH), 8.13 (d, 2H, J= 9.2 Hz, ArH), 
8.25 (d, 1H, J= 6.8 Hz, ArH), 9.66 (s, 1H, ArH); 
13
C-NMR (CDCl3, 400 MHz): 15.34, 
29.65, 101.25, 109.92, 119.52, 121.28, 121.49, 123.21, 124.34, 125.47, 128.51, 128.93, 
135.26, 136.21, 143.33, 143.76, 145.42; MS (m/z, %): 247 (17.75), 246 (100), 245 
(44.57), 231 (10.75), 206 (7.74), 123 (22.06), 115 (11.39), 102 (12.51). Anal. Calcd for 
C17H14N2; C, 82.90; H, 5.73; N, 11.37. Found: C, 82.84; H, 5.76; N, 11.39. 
2-Methyl N-methyl 5-demethyl-ellipticinium iodide (ET-2) 
 ET-1 (500 mg, 2 mmoles) was resuspended in dimethylformamide (5 mL), and 
iodomethane (320 mg, 2.2 mmoles) was added. The reaction mixture was stirred at room 
temperature for 5 h, quenched with cold ether (5 mL), and the resulting precipitate was 
collected by vacuum filtration. The precipitate was washed with cold ethanol (2.5 mL) to 
yield ET-2 as an orange solid. Yield: 350 mg, 44%; mp: 335°C (dec.); IR (KBr) νmax: 
3045 (CH), 2925 (CH), 1610 (C=N) cm
-1
; 
1
H-NMR (DMSO-d6, 400 MHz): δ 3.10 (s, 3H, 
CH3), 3.81 (s, 3H, NCH3), 4.37 (s, 3H, 
+
NCH3), 7.35 (td, 1H, J= 7.6 and 1.2 Hz, ArH), 
7.60 (d, 1H, J= 7.6 Hz, ArH), 7.65 (t, 1H, J= 7.2 Hz, ArH), 7.88 (s, 1H, ArH), 8.19 (d, 1H, 
J= 6.4 Hz, ArH), 8.27 (d, 2H, J= 7.6 Hz, ArH), 9.82 (s, 1H, ArH); 
13
C-NMR (DMSO-d6, 
400 MHz): 15.49, 29.87, 47.33, 101.44, 110.19, 119.89, 121.46, 121.67, 123.72, 124.61, 
125.82, 129.11, 132.87, 134.73, 135.24, 143.58, 145.65, 147.31; MS (m/z, %): 388 (100), 
120 
231 (24.75), 205 (9.62), 115 (14.48). Anal. Calcd for C18H17N2I; C, 55.68; H, 4.41; N, 
7.21. Found: C, 55.62; H, 4.43; N, 7.19 
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